



Rickettsia-Host-Tick Interactions: Knowledge Advances and Gaps

 Hwan Keun Kim^a

^aCenter for Infectious Diseases, Department of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA

ABSTRACT Ticks are hematophagous ectoparasites capable of transmitting multiple human pathogens. Environmental changes have supported the expansion of ticks into new geographical areas that have become the epicenters of tick-borne diseases (TBDs). The spotted fever group (SFG) of *Rickettsia* frequently infects ticks and causes tick-transmitted rickettsioses in areas of endemicity where ixodid ticks support host transmission during blood feeding. Ticks also serve as a reservoir for SFG *Rickettsia*. Among the members of SFG *Rickettsia*, *R. rickettsii* causes Rocky Mountain spotted fever (RMSF), the most lethal TBD in the United States. Cases of RMSF have been reported for over a century in association with several species of ticks in the United States. However, the isolation of *R. rickettsii* from ticks has decreased, and recent serological and epidemiological studies suggest that novel species of SFG *Rickettsia* are responsible for the increased number of cases of RMSF-like rickettsioses in the United States. Recent analyses of rickettsial genomes and advances in genetic and molecular studies of *Rickettsia* provided insights into the biology of *Rickettsia* with the identification of conserved and unique putative virulence genes involved in the rickettsial life cycle. Thus, understanding *Rickettsia*-host-tick interactions mediating successful disease transmission and pathogenesis for SFG rickettsiae remains an active area of research. This review summarizes recent advances in understanding how SFG *Rickettsia* species coopt and manipulate ticks and mammalian hosts to cause rickettsioses, with a particular emphasis on newly described or emerging SFG *Rickettsia* species.

KEYWORDS *Rickettsia*, tick, spotted fever, rickettsiosis, pathogenesis, endothelial cell, macrophages

EVOLUTION OF RICKETTSIA

Rickettsiae (alphaproteobacteria; *Rickettsiales*, *Rickettsiaceae*) are small (0.3- to 0.5- by 0.8- to 2.0- μ m) Gram-negative bacteria with an obligate intracellular life cycle circulating between mammalian hosts and hematophagous arthropod vectors (e.g., ticks, mites, fleas, and lice) in nature. Early studies using electron microscopy identified intracellular *Rickettsia* with a trilaminar cell membrane surrounded by a slime layer (1). The rickettsial outer membrane is decorated with lipopolysaccharides that are highly immunogenic and responsible for cross-reactive Weil-Felix antibodies (2). On the basis of the genome sequence, antigenic properties, and disease attributes, rickettsiae are categorized as belonging to the spotted fever group (SFG), typhus group (TG), transitional group (TRG), and ancestral group (AG) (Table 1) (3, 4). Rickettsiae are transmitted to mammalian hosts during blood feeding by infected ticks and mites or by contaminated feces of infected lice and fleas. Humans do not contribute to rickettsial circulation in nature, except for *Rickettsia prowazekii*, for which they serve as a reservoir and suffer from recurrent Brill-Zinsser disease (5, 6). Comparative and phylogenomic analyses identified that while adapting to an intracellular life cycle, the chromosomes of *Rickettsia* evolved via progressive reduction, resulting in small genomes ranging from 1.1 to 1.5 Mbp (encoding ~800 to 1,300 proteins) with predictions of ~700 core genes, an ~30% G+C content, and a coding capacity of 69 to 84% (7). Through

Editor Karen M. Ottemann, University of California, Santa Cruz

Copyright © 2022 Kim. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to hwan.kim@stonybrook.edu.

The authors declare no conflict of interest.

Published 22 August 2022

TABLE 1 *Rickettsia* groups and diseases

Group	Species	Disease	Vector
Spotted fever ^a	<i>R. rickettsii</i>	Rocky Mountain spotted fever	Tick
	<i>R. conorii</i>	Mediterranean spotted fever	Tick
	<i>R. parkeri</i>	<i>R. parkeri</i> rickettsiosis	Tick
	<i>R. philipii</i> (<i>Rickettsia</i> sp. 364D)	Pacific Coast tick fever	Tick
	<i>R. africae</i>	African tick bite fever	Tick
	<i>R. japonica</i>	Japanese spotted fever	Tick
	<i>R. heilongjiangensis</i>	Far-Eastern spotted fever	Tick
	<i>R. honei</i>	Flinders Island spotted fever	Tick
	<i>R. amblyommatis</i> ^b	Mild spotted fever	Tick
Typhus	<i>R. prowazekii</i>	Epidemic typhus	Louse
	<i>R. typhi</i>	Murine typhus	Flea
Transitional ^a	<i>R. felis</i>	Flea-borne spotted fever	Flea
	<i>R. akari</i>	Rickettsialpox	Mite
Ancestral	<i>R. bellii</i>	Nonpathogenic	Tick
	<i>R. canadensis</i>	Nonpathogenic	Tick

^aA nonexhaustive list.

^bRickettsiae presumptively associated with human diseases.

reductive genome evolution, *Rickettsia* lost genes involved in metabolic pathways and has a limited ability to synthesize amino acids and nucleotides, mimicking symbiotic bacteria (8). To compensate for gene loss, *Rickettsia* species developed parasitic mechanisms whereby a large array of transport systems pilfers essential metabolites for their survival and replication within the host cytosolic compartment (8). Thus, identifying specific metabolic pathways missing in *Rickettsia* may provide critical knowledge in gaps in developing an axenic medium that supports rickettsial extracellular replication and novel therapeutics that target essential transport mechanisms.

Rickettsiae have evolved to adapt to diverse environmental conditions, including various arthropod vectors and mammalian hosts, and display various degrees of mutualism and pathogenicity. For instance, several *R. felis* (TRG) strains have been identified, sequenced, and characterized for their diverse genetic makeup, pathogenicity, and vector adaptations (9). *R. felis* in booklouse (*Liposcelis bostrychophila*) is involved in the development of oocytes, maintained strictly via transovarial transmission, and is considered nonpathogenic in mammalian hosts (10). In contrast, flea-borne *R. felis* is responsible for many febrile diseases of unknown origins in areas of endemicity (11–14). Comparative genome sequence analysis identified genomic sites that are conserved and divergent between flea-derived and booklice-derived *R. felis* strains, suggesting that genetic variability may contribute to vector specificity and virulence in mammalian hosts (15). However, further studies are required to investigate the unique genetic traits of *R. felis*, its adaptation to different arthropod vectors, and their relationship to virulence in mammalian hosts.

Interestingly, *R. prowazekii* (TG), which has the smallest genome, causes the most severe and lethal disease (epidemic typhus), which has claimed countless lives over the last centuries (16). This paradoxical inverse correlation where increased pathogenicity is associated with genome reduction has also been described for other pathogenic bacterial species such as *Mycobacterium leprae*, *Yersinia pestis*, and *Streptococcus suis* (17–19). While we do not fully understand the complex evolutionary processes of rickettsial gene deterioration, comparative and whole-genome sequencing analyses suggest that the increased pathogenicity of *Rickettsia* is not associated with novel virulence gene acquisition but instead is correlated with efficient and/or reduced gene regulation in virulent *Rickettsia* species (16, 20–26). Despite ongoing reductive genome evolution, similar studies identified various degrees of conservation and expansion of genes encoding tetratricopeptide repeats, ankyrin repeats, toxin-antitoxin modules, stress response regulators (SpoT), ADP-ATP translocases, proteins

involved in the type IV secretion system (T4SS), surface cell antigens (Sca), hemolysins, phospholipases, and uncharacterized proteins with putative virulence functions (27–31). Gene rearrangements, deletions, and mutations have been implicated in the attenuated virulence of *Rickettsia*, but additional studies are needed to determine the functional significance of genetic variants (32–34). The information gained from comparing the genomes of *Rickettsia* strains has provided significant insights into the gene conservation, divergence, and evolution of *Rickettsia* and enabled investigators to identify putative virulence genes important for the rickettsial intracellular life cycle in mammalian hosts and arthropod vectors and to correlate these with diverse pathogenic mechanisms subverting host immunity. However, the selective pressure and molecular mechanisms enabling *Rickettsia* species and strains to maintain and reduce their genome sizes remain unknown.

SPOTTED FEVER GROUP RICKETTSIA

Ticks are hematophagous ectoparasites capable of transmitting multiple human pathogens of public health importance. Recent environmental changes have contributed to the expansion and invasion of ticks into new geographical areas that have become the epicenters of tick-borne diseases (TBDs) (35, 36). Ticks require blood meals for their continued development, reproduction, and survival. The SFG rickettsiae infect ticks and cause tick-transmitted rickettsioses in areas of endemicity where ixodid ticks support host transmission through their bites during blood feeding. Infected ticks become a primary reservoir of SFG *Rickettsia* species, providing a lifelong opportunity to transmit and amplify these pathogens in mammalian hosts (Table 1). In North and South America, *Dermacentor variabilis*, *D. andersoni*, *Rhipicephalus sanguineus*, and *Amblyomma sculptum* are confirmed vectors of *R. rickettsii*. In addition, *A. maculatum*, *A. tigrinum*, and *A. triste* transmit *R. parkeri* rickettsioses. In Europe and the Mediterranean littoral to India and Africa, *R. sanguineus* is the most common vector for *R. conorii*. *R. africae* has been associated with several tick species of the genus *Amblyomma* in Africa. In Asia, *R. japonica* has been frequently isolated from several tick species that belong to the genera *Haemaphysalis*, *Ixodes*, and *Dermacentor*. With the advances in molecular genetics in the past decades, several novel SFG rickettsiae have been identified and characterized for their association with tick reservoirs and contributions to numerous tick-borne rickettsioses throughout the world, for instance, *R. heilongjiangensis* in *Dysmicoccus sylvarum* and *Haemaphysalis* ticks and *R. honei* in *Bothriocroton hydrosauri*, *Haemaphysalis novaeguineae*, and *Ixodes* species (37–39). These epidemiological data strongly advocate for the importance of tick surveys in preventing and managing tick-borne rickettsioses and understanding the pathophysiology of *Rickettsia* in tick and host transmission. Antibiotic treatment with doxycycline is most effective when initiated early in the course of tick-borne rickettsioses (40). Delayed diagnosis and antibiotic treatment are associated with adverse clinical outcomes such as increased rates of hospitalization, admission to an intensive care unit, a delayed time to recovery with complications, and mortality (40–42). Increased levels of *Rickettsia*-specific immune titers represent serologic confirmation of rickettsial infections; however, nonspecific clinical symptoms (for instance, fever, headache, myalgias, and nausea) and limited access to molecular diagnostic tools in reference laboratories prohibit the prompt diagnosis and treatment of rickettsial infections. As a result, the actual incidence of tick-borne rickettsioses is predicted to be much higher, and the case fatality rate of SFG rickettsioses remains high in many parts of the world (43–45). Overall, the public health burden of tick-borne rickettsioses remains significantly underestimated.

TICK TRANSMISSION OF SFG RICKETTSIA

During blood feeding by infected ticks, rickettsiae in tick saliva are introduced into the dermis and small capillaries, seeding initial infection with varying degrees of local inflammation and cellular infiltrates such as macrophages (Fig. 1) (46–50). The underlying molecular mechanisms mediating the initial acute phase of tick-borne rickettsiosis in humans are largely unknown, as many patients seek medical interventions several days after the onset of clinical symptoms. However, several factors contribute to the




FIG 1 Life cycle of tick-borne *Rickettsia*. (A) Spotted fever group rickettsiae infect salivary glands, midguts, or ovaries of susceptible ticks. Infected ticks transmit rickettsiae through their bites during blood feeding, along with immunomodulatory components in tick saliva. (B) Within the bloodstream, rickettsiae target vascular endothelial cells, inducing actin-mediated uptake and the subsequent release of rickettsiae into the cytoplasm. (C) The intracellular replication of rickettsiae requires multiple virulence factors for immune evasion, host cell invasion, membrane lysis, and nutrient uptake. (D) Rickettsiae destroy vascular endothelial cells, causing local and systemic vasculitis. Survival of rickettsiae within phagocytes is essential for clinical disease. Infected individuals elicit *Rickettsia*-specific antibodies and T-cell responses for immune protection.

successful transmission of SFG *Rickettsia*, for instance, the duration of tick attachment, bacterial loads in tick saliva, and the transmission efficiency of *Rickettsia*. Under laboratory conditions, *R. rickettsii* transmission occurred as soon as 8 h after *D. variabilis* bites on guinea pigs, and the severity of clinical disease was dependent on the duration of tick attachment (51). This study corroborates reported cases of *R. parkeri* rickettsiosis in patients with <8 h of tick attachment (49, 50). The bacterial loads in tick saliva and salivary glands and the capacity to transmit *R. parkeri* by infected *A. maculatum* ticks played significant roles in successful *R. parkeri* transmission and causing local inflammation at the tick attachment sites on Sprague-Dawley rats (52). Tick saliva contains an arsenal of multiple immunomodulatory agents that affect host hemostasis and immune defense mechanisms (53, 54). Besides facilitating tick attachment and blood feeding, the immunomodulatory properties of tick saliva contribute to the enhanced transmission of several tick-borne pathogens, including SFG *Rickettsia* (53–55). Skin-resident dendritic cells (DCs) sense the local inflammatory environment and regulate tissue homeostasis, immune tolerance, and T-cell responses against invading pathogens (56–59). A recent study reported that prostaglandin E₂ (PGE₂) in *A. sculptum* saliva dampened the proinflammatory immune responses of DCs infected with *R. rickettsii* (60). The abundance of PGE₂ increased as the ticks continued to blood feed, potentially assisting in the survival and hematogenous dissemination of *Rickettsia* (60). Indian rhesus macaques (*Macaca mulatta*) exposed to *A. maculatum* adult ticks and subsequently infected with an intradermal injection of 10⁷ *R. parkeri* cells suffered from persistent *R.*

parkeri infection at the inoculation site (eschar) and systemic dissemination of *R. parkeri*, suggesting that tick feeding introduced immunomodulatory factors and enhanced the pathogenesis of *R. parkeri* rickettsiosis (61). Other investigators utilized mouse infection models to determine the impacts of active tick attachment and blood feeding during *Rickettsia* infection. In one study, infesting *R. sanguineus* nymphal ticks on C3H/HeJ intradermally infected with 10^7 *R. conorii* cells reduced proinflammatory responses but failed to change the histological features and bacterial loads in the lungs (62). However, in a separate study, infesting *A. maculatum* nymphal ticks on C3H/HeJ mice infected via intradermal injection of 5.5×10^6 *R. parkeri* cells supported rickettsial growth, with extensive necrosis and inflammatory immune cell recruitment (63). The *R. parkeri* study utilized laboratory-reared nymphs constitutively infected with "*Candidatus Rickettsia andeanae*," but this nonpathogenic *Rickettsia* species failed to seed infections in mice during blood feeding (63). A point mutation in the coding region of the *tlr4* gene in C3H/HeJ mice interferes with the Toll-like receptor 4 (TLR4)-mediated activation of DCs and natural killer (NK) cells important for innate rickettsial immunity and predisposes the animals to rickettsial infections (64–66). It remains unclear whether different tick species (e.g., *R. sanguineus* and *A. maculatum*) produce different classes and abundances of immunomodulatory molecules that pose various capacities to facilitate SFG *Rickettsia* survival and reduce the proinflammatory immune responses of DCs, NK cells, or other cellular components at the site of infection. Furthermore, additional studies are required to identify specific rickettsial factors that synergize with immunomodulatory factors in tick saliva, contributing to the enhanced transmission and pathogenesis of tick-borne rickettsiosis. For in-depth discussions, interested readers are directed to a recent review article highlighting the multifaceted and complex relationships between *Rickettsia* and arthropod vectors (67).

SFG RICKETTSIA-ENDOTHELIAL CELL INTERACTIONS

In some cases of tick-borne rickettsioses, SFG *Rickettsia* actively replicates at tick bite sites and produces epidermal and dermal necrotic lesions that are characterized as inoculation eschars within a few days of infection. Histopathological analyses often identify vasculitis and necrotic features associated with vascular thrombosis. Numerous clinical reports have documented the presence of multiple eschars on patients infected by several SFG rickettsial agents, such as *R. parkeri*, *R. philipii*, (previously known as *Rickettsia* sp. strain 364D), and *R. africae* (48, 68). While most case studies (~80% of tick-borne rickettsial disease cases reported to the CDC) failed to provide information on eschars, current surveillance data suggest that eschar-associated rickettsial diseases are associated with less virulent tick-borne rickettsial agents (69). A recent investigation developed a mouse infection model (C57BL/6 mice lacking the expression of receptors for type I interferon [IFN-I] and IFN- γ) that recapitulates *R. parkeri* eschar formation upon intradermal inoculation and characterized Sca2-mediated *R. parkeri* dissemination to distal organ tissues, opening a new window of opportunity to improve our understanding of how rickettsial virulence mechanisms impact eschar formation (70).

Within the bloodstream, rickettsiae target and invade vascular endothelial cells and replicate within the cytoplasmic compartment (Fig. 1). Infections with pathogenic SFG *Rickettsia* induce increased vascular permeability associated with rickettsial replication and disruption of vascular endothelial cells with perivascular infiltration of T cells and macrophages. Progressive endothelial cell injury leads to the generation of the characteristic erythematous rash, disseminated vasculitis, cutaneous necrosis, pneumonitis, meningoencephalitis, and multiorgan failure (71). Thus, the molecular interactions between *Rickettsia* and host endothelial cells have a significant role in SFG rickettsioses. Infection of vascular endothelial cells with *Rickettsia* activates a proinflammatory state and induces cytokine and chemokine responses. Human umbilical vein endothelial cells (HUVECs) infected with *R. rickettsii* increased cell-associated interleukin-1 α (IL-1 α) production for the potential activation of IL-1 receptor 1 (IL-1R1) signaling in an intracrine and paracrine manner to coordinate the local inflammatory responses of endothelial cells and recruit professional phagocytes (72, 73). *R. conorii* infections in HUVECs induced cell-

associated IL-1 α production, triggering the secretion of IL-6 and IL-8 and the expression of adhesion molecules, including E-selectin, intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1) (74–76). Similarly, infections with *R. rickettsii*, *R. conorii*, and *R. africae* caused the secretion of two chemokines, IL-8 and monocyte chemoattractant protein 1 (MCP-1, also known as CCL2) from endothelial cells, implying their roles in activating and recruiting neutrophils and monocytes to the sites of infection (75, 77–79). While HUVECs exposed to heat-inactivated *R. conorii* generated a marked release of IL-8 and MCP-1 (CCL2) in a dose- and TLR4-dependent manner, heat-inactivated *R. africae* caused rather modest responses in HUVECs (75). In contrast to the comparable IL-8 levels in serum samples between control and African tick bite fever (ATBF) (*R. africae*) subjects, Mediterranean spotted fever (MSF) patients displayed a marked elevation of serum IL-8, potentially contributing to the distinct clinical features of MSF (75). Previous work demonstrated that IL-8 activates microvascular endothelial cells via CXCR1 and CXCR2 pathways and may contribute to vascular permeability during acute inflammation (80). It is also possible that IL-8 may inhibit and delay endothelial cell apoptosis, providing an intracellular replicative niche for *Rickettsia* (81). *R. conorii* infection of a mouse endothelial cell line, SVEC4-10, primed with IFN- γ or a combination of tumor necrosis factor alpha (TNF- α) and IFN- γ induced the expression of two chemokines, CXCL9 and CXCL10, known to target CXCR3 expressed on T and NK cells (important innate regulators of rickettsial infections) (82). This observation was corroborated by histopathological analysis of organ tissues collected from C3H/HeN mice infected with *R. conorii* (82). Human patients with confirmed cases of MSF (*R. conorii*) in Italy and Spain displayed pronounced increases in serum levels of CXCL10 (83). This was in part due to circulating blood cells releasing CXCL10 and additional inflammatory regulators, which promoted endothelial cells to release additional CXCL10 into the plasma (83).

Endothelial cells express CX3CL1 (fractalkine) as a transmembrane protein for the interaction with its receptor, CX3CR1, which is abundantly expressed on human innate immune cells capable of controlling early rickettsial infections, including NK cells, T cells, and monocytes/macrophages (84). Once cleaved from the surface by ADAM10 and ADAM17, soluble CX3CL1 acts as a classical chemoattractant (85, 86). *In vitro*, *R. rickettsii* infection of HMEC-1 cells exploited microRNA-424 to actively modulate the expression of CX3CL1. While the exact mechanisms remain unknown, *in vivo* C3H/HeN mouse infection studies performed with *R. conorii* confirmed that the peak expression of CX3CL1 coincides with the recruitment of macrophages during the acute phase of systemic endothelial infection (87). On the other hand, increased expression of CX3CL1 on activated endothelial cells can trigger platelet activation via CX3CR1 and enhance platelet adhesion via the glycoprotein Ib α (GPIb α) receptor (88, 89). During rickettsial infections, endothelial cell activation and subsequent injury lead to a dysregulated state of the hemostasis system (90, 91). While a minor reduction in platelet counts has often been reported for tick-borne rickettsiosis, severe coagulopathies, such as deep venous thrombosis and disseminated intravascular coagulation, have been documented for patients infected with pathogenic *Rickettsia* species, including *R. rickettsii*, *R. conorii*, *R. sibirica*, and *R. japonica* (92–95). Such a procoagulant potential has been documented for HUVECs infected with *R. rickettsii*, *R. conorii*, and *R. africae* (96–99). Of note, ATBF (*R. africae*) patients displayed a significantly increased level of soluble CD40 ligand (sCD40L) in serum (99). *In vitro* infection of HUVECs with *R. africae* showed a synergistic contribution of HUVECs and platelets to the elevation of sCD40L in a CX3CL1-dependent manner, potentially contributing to vascular inflammation and dysregulated hemostasis (99). These data illustrate that SFG *Rickettsia* infections of endothelial cells induce common and unique inflammatory responses. It is possible that endothelial cell responses to those species that cause mild or self-limiting tick-borne rickettsioses are beneficial and contribute to the clearance of intracellular *Rickettsia*. On the other hand, highly pathogenic SFG *Rickettsia* species may exploit host inflammatory responses to generate inappropriate local and systemic inflammatory responses, leading to limited or self-destructive hyperactive immune responses. Furthermore, it remains unknown whether specific SFG *Rickettsia* species are equipped with unique virulence factors to modulate endothelial cell responses, contributing to different clinical features. Interested readers are directed to

recently published review articles that provide an excellent and detailed overview of *Rickettsia*-endothelial cell interactions (100, 101).

SURVIVAL OF PATHOGENIC SFG RICKETTSIA IN PROFESSIONAL PHAGOCYTES

As rickettsiae continue to replicate and spread through the vasculature, perivascular neutrophilic and lymphohistiocytic inflammatory cells are recruited to the site of infection to prevent further dissemination of the invading bacteria (Fig. 1) (47, 102, 103). Recent investigations suggest that rickettsial survival in macrophages may determine the basis of rickettsial virulence and pathogenesis. Pathogenic SFG *Rickettsia* species, such as *R. rickettsii*, *R. conorii*, *R. parkeri*, *R. helvetica*, and *R. australis*, have evolved to resist bactericidal mechanisms and establish a replicative niche within the cytosolic compartments of macrophages (104–109). On the other hand, nonpathogenic *R. montanensis* and *R. bellii* fail to escape the phagolysosome and survive within THP-1 macrophages (104, 106). *R. conorii* replication in THP-1 macrophages induced unique proteome signatures (e.g., increased levels of proteins involved in the tricarboxylic acid cycle, oxidative phosphorylation, fatty acid β -oxidation, glutaminolysis, and mitochondrial transport) and altered metabolic and lipid catabolic pathways favoring anti-inflammatory M2 responses (110, 111). On the other hand, *R. helvetica* infection of THP-1 macrophages led to the production of the proinflammatory cytokine TNF- α (109). For *R. parkeri* survival in mouse bone marrow-derived macrophages (BMDMs), outer membrane protein B (OmpB), the most abundant and conserved protein required for the formation of protective surface- and capsule-like layers on *Rickettsia*, played a significant role in preventing the surface polyubiquitylation of OmpA and subsequent autophagy evasion (108, 112). During *R. parkeri* infection of murine BMDMs, *R. parkeri* activated the inflammasome in a caspase 1/11-dependent manner to avoid IFN-I production and the subsequent activation of interferon regulatory factor 5 (IRF5), which upregulates rickettsicidal genes encoding guanylate-binding proteins (GBPs) and inducible nitric oxide synthase (iNOS) (113). *R. australis* infections of human (peripheral blood mononuclear cell- and THP-1-derived) and mouse (BMDM) macrophages also activated inflammasome responses and induced IL-1 β and IL-18 secretion in a caspase 1- and TLR4-dependent manner (107, 114). Furthermore, the activation of the inflammasome contributed to host immune control of *R. australis* in C57BL/6 mice (114). A recent study reported the role of nitric oxide in preventing protein synthesis and restricting the growth of *R. rickettsii* in J774 macrophage-like cells (105). These studies provide evidence that pathogenic *Rickettsia* species may exploit and evade host immune protection mechanisms and establish an intracellular niche for their survival and transmission within macrophages. Tick-borne rickettsioses present different clinical severities, ranging from life-threatening diseases to self-limiting mild cases with no complications. It remains largely unknown how individual pathogenic *Rickettsia* species employ unique or conserved virulence mechanisms to manage and foster intracellular replicative niches in macrophages, professional phagocytes equipped with an impressive armamentarium of antimicrobial mechanisms, and contribute to varying clinical severities. Many previous studies have been conducted with macrophage-like cells or murine macrophages. Although macrophage-like cells are convenient and economical, studies have demonstrated that these cells function differently in many aspects compared to primary macrophages (115). At the same time, mouse models have provided significant insights into rickettsial pathogenesis and host immunity. However, there are substantial differences between mouse and human immunology (116). Thus, such differences should be carefully considered when studying *Rickettsia*-macrophage interactions and their implications for human rickettsiosis.

NOTABLE EMERGING SFG RICKETTSIA SPECIES WITH CONFIRMED OR PRESUMPTIVE HUMAN INFECTIONS

During most of the 20th century, *R. rickettsii* and *R. conorii* were considered the major tick-borne *Rickettsia* species associated with human infections (RMSF and MSF, respectively) in the Americas, Europe, and Africa (117). Over the last decades, investigators have discovered and characterized numerous novel *Rickettsia* species from ticks

but considered them nonpathogenic to humans (117). However, this concept has been challenged extensively as epidemiological analyses, clinical research, and laboratory studies indicate that tick-borne rickettsioses are underdiagnosed and often associated with previously uncharacterized SFG *Rickettsia* species (118). As discussed here and elsewhere, recent investigations describe that emerging SFG *Rickettsia* species are capable of infecting cells in the salivary glands and midguts of ticks, display moderate virulence in *in vitro* and *in vivo* infection models, produce mild-to-moderate clinical disease in patients, and elicit inflammatory and pathogen-specific immune responses after tick transmission. Among many emerging SFG *Rickettsia* species, five such examples are selected and reviewed in detail below to illustrate how recent studies provided insights into understanding *Rickettsia*-host-tick interactions (additional emerging SFG *Rickettsia* species are reviewed in references 118 and 119).

R. parkeri. *R. parkeri* was initially isolated from *A. maculatum* ticks collected from cows in Texas in 1939 and characterized for mild febrile disease with edema and reddening of the scrotum in guinea pigs (120). After >60 years of speculation, the pathogenicity of *R. parkeri* was confirmed with a patient in Virginia presenting relatively mild febrile illness accompanied by multiple eschars and a maculopapular eruption (121). Similar to other tick-borne rickettsial infections, *R. parkeri*-infected patients display a combination of non-specific clinical symptoms (e.g., fever, headache, malaise, and myalgia) and characteristic eschars at the inoculation site of tick attachment (122–124). Some *R. parkeri*-infected patients required hospitalization, but no case fatalities have been reported for *R. parkeri* infections (125). Bioinformatics determined the syntenic organization of the three *R. parkeri* genome sequences with differences in genome sizes (Atlantic Rainforest, 1.35 Mbp; Black Gap, 1.33 Mbp; Portsmouth, 1.30 Mbp) and gene rearrangements, partly due to the presence or absence of *tra* genes (126). *R. parkeri* is associated with several *Amblyomma* ticks (*A. maculatum* as the main vector) in the Americas (127–129). Over the last decades, many tick species, including *A. maculatum*, have expanded their ranges, seeding new habitats and potential hot spots for *R. parkeri* rickettsiosis (130, 131). The distinct geographical distributions of *Amblyomma* species may have contributed to the phylogenetic differentiation and evolutionary adaptation of multiple *R. parkeri* species (132). However, *R. parkeri* infections caused by various *Amblyomma* vectors do not cause significant differences in clinical outcomes (133).

The identification of genes required for the rickettsial intracellular life cycle is an essential step toward understanding the molecular basis of tick-borne rickettsiosis (134). Furthermore, information on the essential molecular mechanisms will assist in deducing vaccine antigens and therapeutic drug targets. Over the last decades, several genetic tools have been developed to create bacterial variants that carry insertional, deletional, or point mutations and to study the consequences of mutations using *in vitro* and *in vivo* infection models. However, the genetic intractability of obligate intracellular bacteria, including *Rickettsia*, has set a significant barrier to genetic tools readily available for free-living bacteria. Despite numerous technical limitations, recent work described the stable transformation of *Rickettsia* with plasmid DNA in the presence of antibiotic selection and established random transposon mutagenesis systems for *R. prowazekii*, *R. rickettsii*, *R. parkeri*, and *R. conorii* (2, 135–137). Using *R. parkeri* insertional mutants, Welch and colleagues demonstrated that (i) Sca2 and RickA mediate actin-based motility in a time-dependent manner in tissue culture cells, (ii) Sca2 is required for *R. parkeri* pathogenesis and dissemination from the inoculation site to internal organs in *lfnar1*^{-/-} *lfngr1*^{-/-} mice, (iii) Sca4 associates with vinculin and mediates the cell-to-cell spread of *R. parkeri*, and (iv) OmpB (Sca5) blocks the ubiquitylation of rickettsial surface antigens to promote autophagy evasion in immune cells and contributes to eschar formation in *lfnar1*^{-/-} *lfngr1*^{-/-} mice (70, 108, 138–140). These studies demonstrate the usefulness of transposon mutagenesis for the study of rickettsial pathogenesis. However, the obstacles to creating a saturated *Rickettsia* mutant library remain due to low transformation efficiency and the use of long-term cultivation to recover, isolate, and determine the genetic lesions of clonal variants in the tissue culture system.

R. africae. Genetic analysis of *R. africae* identified a circular chromosome (1.28 Mbp; 32.4% G+C content) and a circular pRA plasmid (12.3 kbp; 33.4% G+C content), with

1,260 chromosomal and 11 plasmid open reading frames (ORFs) predicted (20). The *R. africae* and *R. conorii* chromosome sequences displayed almost perfect collinearity except for an ~88.5-kbp inversion that harbors *tra* gene orthologs encoding components of a T4SS for conjugal DNA transfer present in *R. africae* but not *R. conorii* (20). The contributions of the T4SS to *R. africae* (or SFG *Rickettsia*) pathogenesis, survival in mammalian and arthropod hosts, and transmission remain unclear (27). *R. africae* causes ATBF and infects multiple species of *Amblyomma* (*A. hebraeum* and *A. variegatum* as the main tick vectors), *Hyalomma*, and *Rhipicephalus* ticks in areas of endemicity in sub-Saharan Africa (141–144). Transstadial and transovarial transmissions of *R. africae* have been reported for *A. hebraeum* (145, 146). A recent PCR analysis identified that most *Amblyomma* ticks (up to 100%) collected from cattle in south and central Mozambique are infected with *R. africae* (143). Similarly, *R. africae* infection was prevalent in *A. variegatum* ticks (87%) on cattle in Madagascar (147). In the coastal region of the Eastern Cape, PCR amplification and sequencing analysis of the *gltA*, *ompA*, *ompB*, *sca4*, and 17kDa genes identified the presence of *R. africae* in *A. hebraeum* (63% adults and 62% nymphs) and blood from cattle (22%) (144). A previous serosurvey of cattle in Zimbabwe identified antibodies cross-reactive to *R. africae*, implying that cattle may play an important role in *R. africae* maintenance in Africa (148). In contrast, a recent study determined that only a small number of *A. variegatum*, *Rhipicephalus decoloratus*, and *R. evertsi mimeticus* ticks collected from domestic cattle in Angola were infected with *R. africae* and found no *R. africae* DNA in bovine blood (149). *R. africae* infections of *A. hebraeum* ticks on goats in Mpumalanga Province (eastern South Africa) and *A. variegatum* ticks on goats, sheep, and cattle in Kenya suggest that other ruminants may serve as alternative hosts for *R. africae* transmission and amplification in nature (142, 150). Additional molecular detection and serosurvey studies are necessary to define mammalian hosts for *R. africae* and their implications for human infections in different geographical areas of Africa.

Most reported cases of ATBF are from international travelers in African countries. In fact, *R. africae* is the second most frequent etiological agent of febrile diseases, after malaria, among tourists returning from southern Africa with a history of travel to grasslands and game parks (estimated infection rate of ~5%) (151, 152). This is partly due to the lack of scientific and public health infrastructures for prompt molecular diagnosis and disease surveillance in these areas of endemicity. Previous seroprevalence studies reported high rates of antibody cross-reactivity to SFG *Rickettsia* in many African populations (153–155). In studies performed in Cameroon, seroprevalence studies identified rates of positivity for antibodies reactive with *R. africae* of 27 to 32%, suggesting that ATBF is common in African countries of endemicity (156, 157). Recent environmental changes, international travel, and shipments contribute to the expansion and invasion of ticks into new geographical habitats. The recent identification of *R. africae*-infected *A. variegatum* on cattle in Corsica, France, and on sheep in Sardinia, Italy (two islands located in the Mediterranean Sea), illustrates the importance of sustained surveillance for the expansion of ticks and the occurrence of associated tick-borne pathogens of veterinary and medical significance (158, 159). Infections with *R. africae* produce non-specific flu-like clinical signs, including headache, fever, eschars, rash, lymphadenopathy, myalgia, chills, malaise, and arthralgia. Patients often report multiple eschars formed at the tick bite sites on the lower extremities, as the main tick vectors, *A. variegatum* and *A. hebraeum*, display aggressive host-seeking behavior, and patients are often bitten by multiple infected ticks simultaneously (152). While *R. conorii* causes MSF in similar geographical areas of Africa, MSF is often associated with a history of contact with *R. sanguineus* and severe clinical outcomes compared to ATBF (160). Most *R. africae* infections cause mild and self-limiting disease, but some severe manifestations, such as cardiomyopathy, neuropathy, cellulitis, retinitis, and chronic fatigue, have been reported in elderly patients (161–163).

***R. heilongjiangensis*.** *R. heilongjiangensis*, first isolated in 1982 from *Dysmicoccus sylvarum* ticks in Suifenhe, a city in the Heilongjiang Province of China, is comprised of

a 1.28-Mbp (32.3% G+C content) circular chromosome and no plasmid DNA (164, 165). Comparative genomics analysis suggests that *R. heilongjiangensis* is closely related to *R. japonica* and causes Far-Eastern spotted fever transmitted by *Haemaphysalis japonica*, *H. concinna*, *H. longicornis*, and *D. sylvarum* in China, Siberia, the Russian Far East, and Japan (25, 39, 166–170). Clinical evaluations revealed common symptoms associated with tick-borne rickettsiosis without significant complications and mortality (39, 166). Patients with a history of a tick bite developed nonspecific clinical symptoms, including sudden onset of fever, chills, and headache, along with maculopapular rash, eschar at the tick bite sites, subcutaneous lymphangitis, and regional lymphadenopathy (39, 166). Mouse infection models have been explored to study the pathological potential of *R. heilongjiangensis*. Intravenous injection of 10^5 viable *R. heilongjiangensis* cells induced hematogenous dissemination, interstitial pneumonia, systemic infection, and multifocal inflammatory lesions with immune cells in multiple organ tissues but failed to cause lethal disease in BALB/c mice (171). Other studies demonstrate that high infectious doses (up to 10^8 cells) of *R. heilongjiangensis* are required to induce nonlethal acute disease when intraperitoneally injected into C3H/HeN or C57BL/6 mice, corroborating clinical observations of mild cases in patients infected with *R. heilongjiangensis* (171–174).

R. honei. *R. honei* causes Flinders Island spotted fever (FISF) in patients bitten by the reptile tick *B. hydrosauri* in Australia and Thai tick typhus in those exposed to *Ixodes granulatus* bites in Thailand (175–178). Whole-genome sequencing of *R. honei* strain RB^T revealed a 1.26-Mbp chromosomal DNA (32.4% G+C content) predicted to harbor 1,284 genes closely related to the genes present in *R. rickettsii*, *R. conorii*, and *R. slovaca* and no plasmid DNA (179). In *B. hydrosauri*, *R. honei* was present in multiple organs, including salivary glands and oocytes, potentially facilitating transstadial and transovarial transmission (178). However, a recent tick survey failed to detect by PCR the presence of *R. honei* in *B. hydrosauri* ticks harvested from skinks (*Tiliqua rugosa*) in southern Australia, where confirmed cases of FISF have been reported (180). Thus, active surveillance of ticks present in areas where FISF is endemic is needed to reveal the primary reservoirs of *R. honei* among different geographical regions (181). *R. honei* subsp. *marmionii* infects *H. novaeguineae* ticks and causes Australian spotted fever (ASF) (182, 183). Clinical symptoms of FISF and ASF are mild and similar to those of other tick-borne rickettsioses and include fever, headache, arthralgia, myalgia, maculopapular/petechial rash, and eschar formation in some cases (176, 177, 182, 183). Of note, atypical chronic and severe infections have been reported in some patients (182, 183). A recent case report described the first probable death of a middle-aged patient infected with *R. honei*, potentially due to delays in diagnosis and doxycycline treatment (184). Cases of FISF and ASF have also been confirmed in a U.S. traveler returning from India and a patient in Nepal, suggesting the broader existence of *R. honei* in multiple geographical areas (185, 186). While previous work described moderate pathogenicity of *R. honei* in guinea pigs and gerbils, additional studies are required to characterize the pathologies associated with *R. honei* infections in animal infection models that reflect FISF and ASF, compare immunopathological features to those of other SFG *Rickettsia* species, and study their role in tick infection and transmission in reptile populations (187).

R. amblyommatis. The genome of *R. amblyommatis* GAT-30V consists of a single chromosome (1.41 Mbp; 32.4% G+C content) and three circular pRM plasmids (32 kbp, 18 kbp, and 23 kbp). Compared to pathogenic SFG *Rickettsia* species (*R. rickettsii* and *R. conorii*), the chromosomal DNA sequence of *R. amblyommatis* displayed high degrees of sequence identity, multiple genetic rearrangements, and regions undergoing gene decay (34). Bioinformatics identified putative virulence genes present with 86 to 95% amino acid identity, but their biological roles in *R. amblyommatis* pathogenesis, transmission, and replication in ticks remain unresolved (30). *R. amblyommatis* frequently infects *Amblyomma americanum* ticks (up to 64%) (188). In recent years, *A. americanum* has rapidly expanded its habitats into the Northeast and Midwest and has become the dominant tick species, contributing to an increased number of patients with tick-borne febrile illnesses of an unknown etiology (189–191). On the other hand, the current prevalence of *R. rickettsii* (RMSF) in *D. variabilis* is estimated to be less than 1% (188). Seroprevalence studies suggest that domestic and wild small mammals (dogs and cats) may contribute to

R. amblyommatis transmission and amplification, with humans as an accidental host (192, 193). However, a definitive mammalian host with systemic *R. amblyommatis* infection as a source of *R. amblyommatis* infection of ticks has not been identified and may vary by geographical location. Nonetheless, *A. americanum* ticks display nondiscriminative and aggressive biting behavior and pose a significant public health concern as they can frequently cause *R. amblyommatis* rickettsiosis and other tick-borne diseases such as ehrlichiosis, Southern tick-associated rash illness, and tularemia (194). In addition, *Amblyomma* tick bites are associated with an unusual life-threatening allergic reaction to oligosaccharide galactose- α -1,3-galactose (α -Gal), also known as meat allergy, but the underlying cause remains unknown (195–197).

A previous case report described a patient bitten by an *A. americanum* tick who developed a macular rash at the tick bite site and had a positive PCR test for *R. amblyommatis* and the absence of *Borrelia*, *Ehrlichia*, *Anaplasma*, *Babesia*, *Bartonella*, and other pathogenic *Rickettsia* species (198). Other studies reported that patients diagnosed with probable RMSF developed *R. amblyommatis*-specific antibodies and presented typical clinical manifestations of tick-borne rickettsioses such as fever, headache, and myalgia, suggesting that *R. amblyommatis* is a presumptive etiological agent for mild rickettsiosis (199–201). Recent and previous investigations studied the virulence potential of *R. amblyommatis* using *in vitro* and *in vivo* infection model systems and largely corroborated the current clinical evidence that *R. amblyommatis* may cause self-limiting mild tick-borne rickettsiosis. *In vitro* tissue culture infection of HMEC-1 cells showed that *R. amblyommatis* displays defective host cell attachment and replicates within host endothelial cells at a lower rate than *R. conorii* (34). Guinea pigs infected with intradermal and intraperitoneal injections of 10^6 cells of *R. amblyommatis* North Texas (isolated from *A. americanum*) did not show any clinical illness but seroconverted by 14 days postinfection (202). In a separate study, intraperitoneal injection of 4×10^6 cells of *R. amblyommatis* 9-CC-3-1 (isolated from *Amblyomma cajennense*) caused vascular inflammation in guinea pigs (203). Of note, both studies demonstrated that guinea pigs infected with *R. amblyommatis* generated cross-reactive immunity that protected the animals against a lethal challenge with *R. rickettsii* (202, 203). A recent comparative analysis of disease severity in guinea pigs infected with *R. rickettsii* or *R. amblyommatis* determined that *R. amblyommatis* infections caused much milder clinical manifestations than *R. rickettsii* (204). Similarly, significantly higher infectious doses of *R. amblyommatis* were required to cause sublethal and lethal diseases in C3H/HeN mice than in those infected with *R. conorii* (34). While these studies corroborate clinical evidence that *R. amblyommatis* may cause mild tick-borne rickettsiosis in some patients, future studies need to utilize tissue culture-based and molecular-based diagnostic approaches to evaluate skin biopsy samples from patients bitten by *A. americanum* ticks, establish a causal relationship for *R. amblyommatis* rickettsiosis, and perform comparative analyses to determine the genetic diversities of *R. amblyommatis* strains present in *A. americanum* ticks in traditional and new habitats in the Americas.

CONCLUDING REMARKS

Several advances have been made within the last decade toward understanding basic *Rickettsia* biology (e.g., genomics, pathogenicity, and vector competence and transmission) and developing molecular tools for *Rickettsia*. Yet some deficiencies (e.g., transmission mechanisms, epidemiology, species diversity, and tick biology) continue to hinder investigative advances for this universal emerging pathogen, highlighting significant research opportunities for discovering novel molecular mechanisms associated with the obligate intracellular life cycle of SFG *Rickettsia* species.

ACKNOWLEDGMENTS

I appreciate the reviewers' constructive criticisms and their effort in reviewing the manuscript, and I apologize for any references that were not included due to space constraints. I express my sincere gratitude to Jorge Benach, David Thanassi, and Adrianus van der Velden for their critical reading of the manuscript and continued support.

I am grateful for prior and ongoing research support from the National Institute of Allergy and Infectious Diseases (AI152208, AI169287, and AI144136 to H.K.K.) of the

National Institutes of Health and the Stony Brook University Office of the Vice President Seed Grant Program.

I declare no competing interests.

REFERENCES

- Silverman DJ, Wisseman CL, Jr. 1978. Comparative ultrastructural study on the cell envelopes of *Rickettsia prowazekii*, *Rickettsia rickettsii*, and *Rickettsia tsutsugamushi*. *Infect Immun* 21:1020–1023. <https://doi.org/10.1128/iai.21.3.1020-1023.1978>.
- Kim HK, Premaratna R, Missiakas DM, Schneewind O. 2019. *Rickettsia conorii* O antigen is the target of bactericidal Weil-Felix antibodies. *Proc Natl Acad Sci U S A* 116:19659–19664. <https://doi.org/10.1073/pnas.1911922116>.
- Gillespie JJ, Beier MS, Rahman MS, Ammerman NC, Shallom JM, Purkayastha A, Sobral BS, Azad AF. 2007. Plasmids and rickettsial evolution: insight from *Rickettsia felis*. *PLoS One* 2:e266. <https://doi.org/10.1371/journal.pone.0000266>.
- Gillespie JJ, Williams K, Shukla M, Snyder EE, Nordberg EK, Ceraul SM, Dharmanolla C, Rainey D, Soneja J, Shallom JM, Vishnubhat ND, Wattam R, Purkayastha A, Czar M, Crasta O, Setubal JC, Azad AF, Sobral BS. 2008. Rickettsia phylogenomics: unwinding the intricacies of obligate intracellular life. *PLoS One* 3:e2018. <https://doi.org/10.1371/journal.pone.0002018>.
- Brill NE. 1952. An acute infectious disease of unknown origin; a clinical study based on 221 cases. *Am J Med* 13:533–541. [https://doi.org/10.1016/0002-9343\(52\)90016-8](https://doi.org/10.1016/0002-9343(52)90016-8).
- Lutwick LI. 2001. Brill-Zinsser disease. *Lancet* 357:1198–1200. [https://doi.org/10.1016/S0140-6736\(00\)04339-7](https://doi.org/10.1016/S0140-6736(00)04339-7).
- Blanc G, Ogata H, Robert C, Audic S, Suhre K, Vestris G, Claverie J-M, Raoult D. 2007. Reductive genome evolution from the mother of Rickettsia. *PLoS Genet* 3:e14. <https://doi.org/10.1371/journal.pgen.0030014>.
- Driscoll TP, Verhoeve VI, Guillotte ML, Lehman SS, Rennoll SA, Beier-Sexton M, Rahman MS, Azad AF, Gillespie JJ. 2017. Wholly Rickettsial Reconstructed metabolic profile of the quintessential bacterial parasite of eukaryotic cells. *mBio* 8:e00859-17. <https://doi.org/10.1128/mBio.00859-17>.
- Brown LD, Macaluso KR. 2016. *Rickettsia felis*, an emerging flea-borne rickettsiosis. *Curr Trop Med Rep* 3:27–39. <https://doi.org/10.1007/s40475-016-0070-6>.
- Thepparit C, Sunyakumthorn P, Guillotte ML, Popov VL, Foil LD, Macaluso KR. 2011. Isolation of a rickettsial pathogen from a non-hematophagous arthropod. *PLoS One* 6:e16396. <https://doi.org/10.1371/journal.pone.0016396>.
- Yang WH, Hsu MS, Shu PY, Tsai KH, Fang CT. 2021. Neglected human *Rickettsia felis* infection in Taiwan: a retrospective seroepidemiological survey of patients with suspected rickettsioses. *PLoS Negl Trop Dis* 15:e0009355. <https://doi.org/10.1371/journal.pntd.0009355>.
- Sothmann P, Keller C, Krumkamp R, Kreuels B, Aldrich C, Sarpong N, Steierberg S, Winter D, Boehn KG, Owusu-Dabo E, May J, Eibach D. 2017. *Rickettsia felis* infection in febrile children, Ghana. *Am J Trop Med Hyg* 96:783–785. <https://doi.org/10.4269/ajtmh.16-0754>.
- Maina AN, Fogarty C, Krueger L, Macaluso KR, Odhiambo A, Nguyen K, Farris CM, Luce-Fedrow A, Bennett S, Jiang J, Sun S, Cummings RF, Richards AL. 2016. Rickettsial infections among *Ctenocephalides felis* and host animals during a flea-borne rickettsioses outbreak in Orange County, California. *PLoS One* 11:e0160604. <https://doi.org/10.1371/journal.pone.0160604>.
- Richards AL, Jiang J, Omulo S, Dare R, Abdurahman K, Ali A, Sharif SK, Feikin DR, Breiman RF, Njenga MK. 2010. Human infection with *Rickettsia felis*, Kenya. *Emerg Infect Dis* 16:1081–1086. <https://doi.org/10.3201/eid1607.091885>.
- Gillespie JJ, Driscoll TP, Verhoeve VI, Utsuki T, Husseneder C, Chouljenko VN, Azad AF, Macaluso KR. 2014. Genomic diversification in strains of *Rickettsia felis* isolated from different arthropods. *Genome Biol Evol* 7:35–56. <https://doi.org/10.1093/gbe/evu262>.
- Andersson SG, Zomorodipour A, Andersson JO, Sicheritz-Pontén T, Alsmark UC, Podowski RM, Näslund AK, Eriksson AS, Winkler HH, Kurland CG. 1998. The genome sequence of *Rickettsia prowazekii* and the origin of mitochondria. *Nature* 396:133–140. <https://doi.org/10.1038/24094>.
- Murray GGR, Charlesworth J, Miller EL, Casey MJ, Lloyd CT, Gottschalk M, Tucker AWD, Welch JJ, Weinert LA. 2021. Genome reduction is associated with bacterial pathogenicity across different scales of temporal and ecological divergence. *Mol Biol Evol* 38:1570–1579. <https://doi.org/10.1093/molbev/msaa323>.
- Singh P, Benjak A, Schuenemann VJ, Herbig A, Avanzi C, Busso P, Nieselt K, Krause J, Vera-Cabrera L, Cole ST. 2015. Insight into the evolution and origin of leprosy bacilli from the genome sequence of *Mycobacterium lepromatosis*. *Proc Natl Acad Sci U S A* 112:4459–4464. <https://doi.org/10.1073/pnas.1421504112>.
- Keller M, Spyrou MA, Scheib CL, Neumann GU, Kröpelin A, Haas-Gebhard B, Pfüffgen B, Haberstroh J, Ribera I, Lacomba A, Raynaud C, Cessford C, Durand R, Stadler P, Nägele K, Bates JS, Trautmann B, Inskip SA, Peters J, Robb JE, Kivisild T, Castex D, McCormick M, Bos KI, Harbeck M, Herbig A, Krause J. 2019. Ancient *Yersinia pestis* genomes from across Western Europe reveal early diversification during the first pandemic (541–750). *Proc Natl Acad Sci U S A* 116:12363–12372. <https://doi.org/10.1073/pnas.1820447116>.
- Fournier P-E, El Karkouri K, Leroy Q, Robert C, Giumelli B, Renesto P, Socolovschi C, Parola P, Audic S, Raoult D. 2009. Analysis of the Rickettsia africae genome reveals that virulence acquisition in Rickettsia species may be explained by genome reduction. *BMC Genomics* 10:166. <https://doi.org/10.1186/1471-2164-10-166>.
- McLeod MP, Qin X, Karpathy SE, Gioia J, Highlander SK, Fox GE, McNeill TZ, Jiang H, Muzny D, Jacob LS, Hawes AC, Sodergren E, Gill R, Hume J, Morgan M, Fan G, Amin AG, Gibbs RA, Hong C, Yu X-J, Walker DH, Weinstock GM. 2004. Complete genome sequence of *Rickettsia typhi* and comparison with sequences of other rickettsiae. *J Bacteriol* 186:5842–5855. <https://doi.org/10.1128/JB.186.17.5842-5855.2004>.
- Ogata H, Renesto P, Audic S, Robert C, Blanc G, Fournier P-E, Parinello H, Claverie J-M, Raoult D. 2005. The genome sequence of *Rickettsia felis* identifies the first putative conjugative plasmid in an obligate intracellular parasite. *PLoS Biol* 3:e248. <https://doi.org/10.1371/journal.pbio.0030248>.
- Londoño AF, Mendell NL, Valbuena GA, Routh AL, Wood TG, Widen SG, Rodas JD, Walker DH, Bouyer DH. 2019. Whole-genome sequence of *Rickettsia parkeri* strain Atlantic Rainforest, isolated from a Colombian tick. *Microbiol Resour Annot* 8:e00684-19. <https://doi.org/10.1128/MRA.00684-19>.
- Matsunami M, Ogawa M, Takaoka N, Hanaoka N, Toh H, Yamashita A, Oshima K, Hirakawa H, Kuhara S, Suzuki H, Hattori M, Kishimoto T, Ando S, Azuma Y, Shirai M. 2013. Complete genomic DNA sequence of the East Asian spotted fever disease agent *Rickettsia japonica*. *PLoS One* 8:e71861. <https://doi.org/10.1371/journal.pone.0071861>.
- Kasama K, Fujita H, Yamamoto S, Ooka T, Gotoh Y, Ogura Y, Ando S, Hayashi T. 2019. Genomic features of *Rickettsia heilongjiangensis* revealed by intra-species comparison and detailed comparison with *Rickettsia japonica*. *Front Microbiol* 10:2787. <https://doi.org/10.3389/fmicb.2019.02787>.
- Ogata H, Audic S, Renesto-Audiffren P, Fournier PE, Barbe V, Samson D, Roux V, Cossart P, Weissenbach J, Claverie JM, Raoult D. 2001. Mechanisms of evolution in *Rickettsia conorii* and *R. prowazekii*. *Science* 293:2093–2098. <https://doi.org/10.1126/science.1061471>.
- Gillespie JJ, Phan IQH, Driscoll TP, Guillotte ML, Lehman SS, Rennoll-Bankert KE, Subramanian S, Beier-Sexton M, Myler PJ, Rahman MS, Azad AF. 2016. The Rickettsia type IV secretion system: unrealized complexity fired by gene family expansion. *Pathog Dis* 74:ftw058. <https://doi.org/10.1093/femspd/ftw058>.
- Sears KT, Ceraul SM, Gillespie JJ, Allen ED, Popov VL, Ammerman NC, Rahman MS, Azad AF. 2012. Surface proteome analysis and characterization of surface cell antigen (Sca) or autotransporter family of *Rickettsia typhi*. *PLoS Pathog* 8:e1002856. <https://doi.org/10.1371/journal.ppat.1002856>.
- Rahman MS, Gillespie JJ, Kaur SJ, Sears KT, Ceraul SM, Beier-Sexton M, Azad AF. 2013. *Rickettsia typhi* possesses phospholipase A2 enzymes that are involved in infection of host cells. *PLoS Pathog* 9:e1003399. <https://doi.org/10.1371/journal.ppat.1003399>.
- Gillespie JJ, Kaur SJ, Rahman MS, Rennoll-Bankert K, Sears KT, Beier-Sexton M, Azad AF. 2015. Secretome of obligate intracellular *Rickettsia*. *FEMS Microbiol Rev* 39:47–80. <https://doi.org/10.1111/1574-6976.12084>.
- Lehman SS, Noriea NF, Aistleitner K, Clark TR, Dooley CA, Nair V, Kaur SJ, Rahman MS, Gillespie JJ, Azad AF, Hackstadt T. 2018. The rickettsial ankyrin repeat protein 2 is a type IV secreted effector that associates with the endoplasmic reticulum. *mBio* 9:e00975-18. <https://doi.org/10.1128/mBio.00975-18>.
- Felsheim RF, Kurtti TJ, Munderloh UG. 2009. Genome sequence of the endosymbiont *Rickettsia peacockii* and comparison with virulent *Rickettsia rickettsii*: identification of virulence factors. *PLoS One* 4:e8361. <https://doi.org/10.1371/journal.pone.0008361>.
- Clark TR, Noriea NF, Bublitz DC, Ellison DW, Martens C, Lutter EI, Hackstadt T. 2015. Comparative genome sequencing of *Rickettsia rickettsii* strains that

- differ in virulence. *Infect Immun* 83:1568–1576. <https://doi.org/10.1128/IAI.03140-14>.
34. Yen W-Y, Stern K, Mishra S, Helminiak L, Sanchez-Vicente S, Kim HK. 2021. Virulence potential of *Rickettsia amblyommatis* for spotted fever pathogenesis in mice. *Pathog Dis* 79:ftab024. <https://doi.org/10.1093/femspd/ftab024>.
 35. Sonenshine DE. 2018. Range expansion of tick disease vectors in North America: implications for spread of tick-borne disease. *Int J Environ Res Public Health* 15:478. <https://doi.org/10.3390/ijerph15030478>.
 36. Eisen RJ, Kugeler KJ, Eisen L, Beard CB, Paddock CD. 2017. Tick-borne zoonoses in the United States: persistent and emerging threats to human health. *ILAR J* 58:319–335. <https://doi.org/10.1093/ilar/ilx005>.
 37. Mediannikov O, Sidelnikov Y, Ivanov L, Fournier P-E, Tarasevich I, Raoult D. 2006. Far Eastern tick-borne rickettsiosis: identification of two new cases and tick vector. *Ann N Y Acad Sci* 1078:80–88. <https://doi.org/10.1196/annals.1374.010>.
 38. Fournier P-E, Allombert C, Supputamongkol Y, Caruso G, Brouqui P, Raoult D. 2004. Aneruptive fever associated with antibodies to *Rickettsia helvetica* in Europe and Thailand. *J Clin Microbiol* 42:816–818. <https://doi.org/10.1128/JCM.42.2.816-818.2004>.
 39. Ando S, Kurosawa M, Sakata A, Fujita H, Sakai K, Sekine M, Katsumi M, Saitou W, Yano Y, Takada N, Takano A, Kawabata H, Hanaoka N, Watanabe H, Kurane I, Kishimoto T. 2010. Human *Rickettsia heilongjiangensis* infection, Japan. *Emerg Infect Dis* 16:1306–1308. <https://doi.org/10.3201/eid1608.100049>.
 40. Regan JJ, Traeger MS, Humpherys D, Mahoney DL, Martinez M, Emerson GL, Tack DM, Geissler A, Yasmin S, Lawson R, Williams V, Hamilton C, Levy C, Komatsu K, Yost DA, McQuiston JH. 2015. Risk factors for fatal outcome from Rocky Mountain spotted fever in a highly endemic area—Arizona, 2002–2011. *Clin Infect Dis* 60:1659–1666. <https://doi.org/10.1093/cid/civ116>.
 41. Holman RC, Paddock CD, Curns AT, Krebs JW, McQuiston JH, Childs JE. 2001. Analysis of risk factors for fatal Rocky Mountain spotted fever: evidence for superiority of tetracyclines for therapy. *J Infect Dis* 184:1437–1444. <https://doi.org/10.1086/324372>.
 42. Kirkland KB, Wilkinson WE, Sexton DJ. 1995. Therapeutic delay and mortality in cases of Rocky Mountain spotted fever. *Clin Infect Dis* 20:1118–1121. <https://doi.org/10.1093/clinids/20.5.1118>.
 43. Álvarez-López DI, Ochoa-Mora E, Nichols Heitman K, Binder AM, Álvarez-Hernández G, Armstrong PA. 2021. Epidemiology and clinical features of Rocky Mountain spotted fever from enhanced surveillance, Sonora, Mexico: 2015–2018. *Am J Trop Med Hyg* 104:190–197. <https://doi.org/10.4269/ajtmh.20-0854>.
 44. Salje J, Weitzel T, Newton PN, Varghese GM, Day N. 2021. Rickettsial infections: a blind spot in our view of neglected tropical diseases. *PLoS Negl Trop Dis* 15:e0009353. <https://doi.org/10.1371/journal.pntd.0009353>.
 45. Biswal M, Krishnamoorthi S, Bisht K, Sehgal A, Kaur J, Sharma N, Suri V, Sethi S. 2020. Rickettsial diseases: not uncommon causes of acute febrile illness in India. *Trop Med Infect Dis* 5:59. <https://doi.org/10.3390/tropicalmed5020059>.
 46. Walker DH, Cain BG, Olmstead PM. 1978. Laboratory diagnosis of Rocky Mountain spotted fever by immunofluorescent demonstration of *Rickettsia* in cutaneous lesions. *Am J Clin Pathol* 69:619–623. <https://doi.org/10.1093/ajcp/69.6.619>.
 47. Jia N, Liu H-B, Zheng Y-C, Shi W-Q, Wei R, Chu Y-L, Ning N-Z, Jiang B-G, Jiang R-R, Li T, Huo Q-B, Bian C, Liu X, Sun Y, Li L-F, Wang Q, Wei W, Wang Y-W, Jongejan F, Jiang J-F, Song J-L, Wang H, Cao W-C. 2020. Cutaneous immunoprofiles of three spotted fever group *Rickettsia* cases. *Infect Immun* 88:e00686-19. <https://doi.org/10.1128/IAI.00686-19>.
 48. Cragun WC, Bartlett BL, Ellis MW, Hoover AZ, Tying SK, Mendoza N, Vento TJ, Nicholson WL, Eremeeva ME, Olano JP, Rapini RP, Paddock CD. 2010. The expanding spectrum of eschar-associated rickettsioses in the United States. *Arch Dermatol* 146:641–648. <https://doi.org/10.1001/archdermatol.2010.48>.
 49. Whitman TJ, Richards AL, Paddock CD, Tamminga CL, Sniezek PJ, Jiang J, Byers DK, Sanders JW. 2007. *Rickettsia parkeri* infection after tick bite, Virginia. *Emerg Infect Dis* 13:334–336. <https://doi.org/10.3201/eid1302.061295>.
 50. Herrick KL, Pena SA, Yaglom HD, Layton BJ, Moors A, Loftis AD, Condit ME, Singleton J, Kato CY, Denison AM, Ng D, Mertins JW, Paddock CD. 2016. *Rickettsia parkeri* rickettsiosis, Arizona, USA. *Emerg Infect Dis* 22:780–785. <https://doi.org/10.3201/eid2205.151824>.
 51. Levin ML, Ford SL, Hartzler K, Krapiunaya L, Stanley H, Snellgrove AN. 2020. Minimal duration of tick attachment sufficient for transmission of infectious *Rickettsia rickettsii* (*Rickettsiales: Rickettsiaceae*) by its primary vector *Dermacentor variabilis* (*Acari: Ixodidae*): duration of rickettsial reactivation in the vector revisited. *J Med Entomol* 57:585–594. <https://doi.org/10.1093/jme/tjz191>.
 52. Suwanbongkot C, Langohr IM, Harris EK, Dittmar W, Christofferson RC, Macaluso KR. 2019. Spotted fever group *Rickettsia* infection and transmission dynamics in *Amblyomma maculatum*. *Infect Immun* 87:e00804-18. <https://doi.org/10.1128/IAI.00804-18>.
 53. Aounallah H, Bensaoud C, M'ghirbi Y, Faria F, Chmellar J, Kotsyfakis M. 2020. Tick salivary compounds for targeted immunomodulatory therapy. *Front Immunol* 11:583845. <https://doi.org/10.3389/fimmu.2020.583845>.
 54. Oliva Chávez AS, Wang X, Marnin L, Archer NK, Hammond HL, Carroll EEM, Shaw DK, Tully BG, Buskirk AD, Ford SL, Butler LR, Shahi P, Morozova K, Clement CC, Lawres L, O'Neal AJ, Mamoun CB, Mason KL, Hobbs BE, Scoles GA, Barry EM, Sonenshine DE, Pal U, Valenzuela JG, Szein MB, Pasetti MF, Levin ML, Kotsyfakis M, Jay SM, Huntley JF, Miller LS, Santambrogio L, Pedra JHF. 2021. Tick extracellular vesicles enable arthropod feeding and promote distinct outcomes of bacterial infection. *Nat Commun* 12:3696. <https://doi.org/10.1038/s41467-021-23900-8>.
 55. Wikel S. 2013. Ticks and tick-borne pathogens at the cutaneous interface: host defenses, tick countermeasures, and a suitable environment for pathogen establishment. *Front Microbiol* 4:337. <https://doi.org/10.3389/fmicb.2013.00337>.
 56. Pasparakis M, Haase I, Nestle FO. 2014. Mechanisms regulating skin immunity and inflammation. *Nat Rev Immunol* 14:289–301. <https://doi.org/10.1038/nri3646>.
 57. Malissen B, Tamoutounour S, Henri S. 2014. The origins and functions of dendritic cells and macrophages in the skin. *Nat Rev Immunol* 14:417–428. <https://doi.org/10.1038/nri3683>.
 58. Hasegawa H, Matsumoto T. 2018. Mechanisms of tolerance induction by dendritic cells in vivo. *Front Immunol* 9:350. <https://doi.org/10.3389/fimmu.2018.00350>.
 59. Worbs T, Hammerschmidt SI, Forster R. 2017. Dendritic cell migration in health and disease. *Nat Rev Immunol* 17:30–48. <https://doi.org/10.1038/nri.2016.116>.
 60. Esteves E, Bizzarro B, Costa FB, Ramírez-Hernández A, Peti APF, Cataneo AHD, Wowk PF, Timóteo RP, Labruna MB, Silva Junior PI, Silva CL, Faccioli LH, Fogaça AC, Sorgi CA, Sá-Nunes A. 2019. *Amblyomma sculptum* salivary PGE2 modulates the dendritic cell-*Rickettsia rickettsii* interactions in vitro and in vivo. *Front Immunol* 10:118. <https://doi.org/10.3389/fimmu.2019.00118>.
 61. Banajee KH, Embers ME, Langohr IM, Doyle LA, Hasenkampf NR, Macaluso KR. 2015. *Amblyomma maculatum* feeding augments *Rickettsia parkeri* infection in a rhesus macaque model: a pilot study. *PLoS One* 10:e0135175. <https://doi.org/10.1371/journal.pone.0135175>.
 62. Milhano N, Saito TB, Bechelli J, Fang R, Vilhena M, De Sousa R, Walker DH. 2015. The role of *Rhipicephalus sanguineus sensu lato* saliva in the dissemination of *Rickettsia conorii* in C3H/HeJ mice. *Med Vet Entomol* 29:225–229. <https://doi.org/10.1111/mve.12118>.
 63. Grasperge BJ, Morgan TW, Paddock CD, Peterson KE, Macaluso KR. 2014. Feeding by *Amblyomma maculatum* (*Acari: Ixodidae*) enhances *Rickettsia parkeri* (*Rickettsiales: Rickettsiaceae*) infection in the skin. *J Med Entomol* 51:855–863. <https://doi.org/10.1093/jme/51.4.855>.
 64. Jordan JM, Woods ME, Olano J, Walker DH. 2008. The absence of Toll-like receptor 4 signaling in C3H/HeJ mice predisposes them to overwhelming rickettsial infection and decreased protective Th1 responses. *Infect Immun* 76:3717–3724. <https://doi.org/10.1128/IAI.00311-08>.
 65. Jordan JM, Woods ME, Soong L, Walker DH. 2009. *Rickettsia* stimulate dendritic cells through Toll-like receptor 4, leading to enhanced NK cell activation in vivo. *J Infect Dis* 199:236–242. <https://doi.org/10.1086/595833>.
 66. Fang R, Ismail N, Walker DH. 2012. Contribution of NK cells to the innate phase of host protection against an intracellular bacterium targeting systemic endothelium. *Am J Pathol* 181:185–195. <https://doi.org/10.1016/j.ajpath.2012.03.020>.
 67. Laukaitis HJ, Macaluso KR. 2021. Unpacking the intricacies of *Rickettsia* vector interactions. *Trends Parasitol* 37:734–746. <https://doi.org/10.1016/j.pt.2021.05.008>.
 68. Lepidi H, Fournier PE, Raoult D. 2006. Histologic features and immunodetection of African tick-bite fever eschar. *Emerg Infect Dis* 12:1332–1337. <https://doi.org/10.3201/eid1209.051540>.
 69. Drexler N, Nichols Heitman K, Cherry C. 2020. Description of eschar-associated rickettsial diseases using passive surveillance data—United States, 2010–2016. *MMWR Morb Mortal Wkly Rep* 68:1179–1182. <https://doi.org/10.15585/mmwr.mm68152a2>.
 70. Burke TP, Engström P, Tran CJ, Langohr IM, Glasner DR, Espinosa DA, Harris E, Welch MD. 2021. Interferon receptor-deficient mice are susceptible to eschar-associated rickettsiosis. *Elife* 10:e67029. <https://doi.org/10.7554/eLife.67029>.

71. Walker DH, Gear JH. 1985. Correlation of the distribution of *Rickettsia conorii*, microscopic lesions, and clinical features in South African tick bite fever. *Am J Trop Med Hyg* 34:361–371. <https://doi.org/10.4269/ajtmh.1985.34.361>.
72. Sporn LA, Marder VJ. 1996. Interleukin-1 alpha production during *Rickettsia rickettsii* infection of cultured endothelial cells: potential role in autocrine cell stimulation. *Infect Immun* 64:1609–1613. <https://doi.org/10.1128/iai.64.5.1609-1613.1996>.
73. Di Paolo NC, Shayakhmetov DM. 2016. Interleukin 1alpha and the inflammatory process. *Nat Immunol* 17:906–913. <https://doi.org/10.1038/ni.3503>.
74. Kaplanski G, Teyssie N, Farnarier C, Kaplanski S, Lissitzky JC, Durand JM, Soubeyrand J, Dinarello CA, Bongrand P. 1995. IL-6 and IL-8 production from cultured human endothelial cells stimulated by infection with *Rickettsia conorii* via a cell-associated IL-1 alpha-dependent pathway. *J Clin Invest* 96:2839–2844. <https://doi.org/10.1172/JCI118354>.
75. Damás JK, Davi G, Jensenius M, Santilli F, Otterdal K, Ueland T, Flo TH, Lien E, Espevik T, Frøland SS, Vitale G, Raoult D, Aukrust P. 2009. Relative chemokine and adhesion molecule expression in Mediterranean spotted fever and African tick bite fever. *J Infect* 58:68–75. <https://doi.org/10.1016/j.jinf.2008.11.008>.
76. Dignat-George F, Teyssie N, Mutin M, Bardin N, Lesaulé G, Raoult D, Sampol J. 1997. *Rickettsia conorii* infection enhances vascular cell adhesion molecule-1 and intercellular adhesion molecule-1-dependent mononuclear cell adherence to endothelial cells. *J Infect Dis* 175:1142–1152. <https://doi.org/10.1086/520353>.
77. Rydkina E, Turpin LC, Sahni SK. 2010. *Rickettsia rickettsii* infection of human macrovascular and microvascular endothelial cells reveals activation of both common and cell type-specific host response mechanisms. *Infect Immun* 78:2599–2606. <https://doi.org/10.1128/IAI.01335-09>.
78. Clifton DR, Rydkina E, Huyck H, Pryhuber G, Freeman RS, Silverman DJ, Sahni SK. 2005. Expression and secretion of chemotactic cytokines IL-8 and MCP-1 by human endothelial cells after *Rickettsia rickettsii* infection: regulation by nuclear transcription factor NF-kappaB. *Int J Med Microbiol* 295:267–278. <https://doi.org/10.1016/j.ijmm.2005.05.006>.
79. Rydkina E, Silverman DJ, Sahni SK. 2005. Activation of p38 stress-activated protein kinase during *Rickettsia rickettsii* infection of human endothelial cells: role in the induction of chemokine response. *Cell Microbiol* 7:1519–1530. <https://doi.org/10.1111/j.1462-5822.2005.00574.x>.
80. Schraufstatter IU, Chung J, Burger M. 2001. IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. *Am J Physiol Lung Cell Mol Physiol* 280:L1094–L1103. <https://doi.org/10.1152/ajplung.2001.280.6.L1094>.
81. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. 2003. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. *J Immunol* 170:3369–3376. <https://doi.org/10.4049/jimmunol.170.6.3369>.
82. Valbuena G, Bradford W, Walker DH. 2003. Expression analysis of the T-cell-targeting chemokines CXCL9 and CXCL10 in mice and humans with endothelial infections caused by *Rickettsia* of the spotted fever group. *Am J Pathol* 163:1357–1369. [https://doi.org/10.1016/S0002-9440\(10\)63494-3](https://doi.org/10.1016/S0002-9440(10)63494-3).
83. Otterdal K, Portillo A, Astrup E, Ludviksen J, Davi G, Holm S, Santilli F, Vitale G, Raoult D, Olano JP, Schjalm C, Halvorsen B, Oteo JA, Mollnes TE, Aukrust P, Nilsson PH. 2016. High serum CXCL10 in *Rickettsia conorii* infection is endothelial cell mediated subsequent to whole blood activation. *Cytokine* 83:269–274. <https://doi.org/10.1016/j.cyto.2016.05.006>.
84. Imaizumi T, Yoshida H, Satoh K. 2004. Regulation of CX3CL1/fractalkine expression in endothelial cells. *J Atheroscler Thromb* 11:15–21. <https://doi.org/10.5551/jat.11.15>.
85. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen K-J, Rose-John S, Ludwig A. 2003. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. *Blood* 102:1186–1195. <https://doi.org/10.1182/blood-2002-12-3775>.
86. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW. 2001. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). *J Biol Chem* 276:37993–38001. <https://doi.org/10.1074/jbc.M106434200>.
87. Valbuena G, Walker DH. 2005. Expression of CX3CL1 (fractalkine) in mice with endothelial-target *rickettsii* infection of the spotted-fever group. *Virchows Arch* 446:21–27. <https://doi.org/10.1007/s00428-004-1120-3>.
88. Meyer dos Santos S, Klinkhardt U, Scholich K, Nelson K, Monsefi N, Deckmyn H, Kuczka K, Zorn A, Harder S. 2011. The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glycoprotein Ib. *Blood* 117:4999–5008. <https://doi.org/10.1182/blood-2011-02-335471>.
89. Schäfer A, Schulz C, Eigenthaler M, Fraccarollo D, Kobsar A, Gawaz M, Ertl G, Walter U, Bauersachs J. 2004. Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. *Blood* 103:407–412. <https://doi.org/10.1182/blood-2002-10-3260>.
90. Elghetany MT, Walker DH. 1999. Hemostatic changes in Rocky Mountain spotted fever and Mediterranean spotted fever. *Am J Clin Pathol* 112:159–168. <https://doi.org/10.1093/ajcp/112.2.159>.
91. Schmaier AH, Srikanth S, Elghetany MT, Normolle D, Gokhale S, Feng HM, Walker DH. 2001. Hemostatic/fibrinolytic protein changes in C3H/HeN mice infected with *Rickettsia conorii*—a model for Rocky Mountain spotted fever. *Thromb Haemost* 86:871–879. <https://doi.org/10.1055/s-0037-1616145>.
92. Luke N, Munasinghe H, Balasooriya L, Premaratna R. 2017. Widespread subcutaneous necrosis in spotted fever group rickettsioses from the coastal belt of Sri Lanka—a case report. *BMC Infect Dis* 17:278. <https://doi.org/10.1186/s12879-017-2375-z>.
93. Miyashima Y, Iwamura M, Shibata M, Miyabe Y, Kawai Y, Kaihara M, Mitogawa T, Harada M. 2018. Prediction of disseminated intravascular coagulation by liver function tests in patients with Japanese spotted fever. *Intern Med* 57:197–202. <https://doi.org/10.2169/internalmedicine.8420-16>.
94. Gaillard E, Socolovschi C, Fourcade C, Lavigne JP, Raoult D, Sotto A. 2015. A case of severe sepsis with disseminated intravascular coagulation during *Rickettsia sibirica mongolitimonae* infection. *Med Mal Infect* 45:57–59. (In French.) <https://doi.org/10.1016/j.medmal.2014.10.005>.
95. Bacci MR, Namura JJ. 2012. Association between sepsis and Rocky Mountain spotted fever. *BMJ Case Rep* 2012:bcr2012007024. <https://doi.org/10.1136/bcr-2012-007024>.
96. Sporn LA, Haidaris PJ, Shi RJ, Nemerson Y, Silverman DJ, Marder VJ. 1994. *Rickettsia rickettsii* infection of cultured human endothelial cells induces tissue factor expression. *Blood* 83:1527–1534. <https://doi.org/10.1182/blood.V83.6.1527.1527>.
97. Teyssie N, Arnoux D, George F, Sampol J, Raoult D. 1992. von Willebrand factor release and thrombomodulin and tissue factor expression in *Rickettsia conorii*-infected endothelial cells. *Infect Immun* 60:4388–4393. <https://doi.org/10.1128/iai.60.10.4388-4393.1992>.
98. Drancourt M, Alessi MC, Levy PY, Juhan-Vague I, Raoult D. 1990. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by *Rickettsia conorii*- and *Rickettsia rickettsii*-infected cultured endothelial cells. *Infect Immun* 58:2459–2463. <https://doi.org/10.1128/iai.58.8.2459-2463.1990>.
99. Damás JK, Jensenius M, Ueland T, Otterdal K, Yndestad A, Frøland SS, Rolain J-M, Myrvang B, Raoult D, Aukrust P. 2006. Increased levels of soluble CD40L in African tick bite fever: possible involvement of TLRs in the pathogenic interaction between *Rickettsia africae*, endothelial cells, and platelets. *J Immunol* 177:2699–2706. <https://doi.org/10.4049/jimmunol.177.4.2699>.
100. Sahni A, Fang R, Sahni SK, Walker DH. 2019. Pathogenesis of rickettsial diseases: pathogenic and immune mechanisms of an endotheliotropic infection. *Annu Rev Pathol* 14:127–152. <https://doi.org/10.1146/annurev-pathmechdis-012418-012800>.
101. Salje J. 2021. Cells within cells: rickettsiales and the obligate intracellular bacterial lifestyle. *Nat Rev Microbiol* 19:375–390. <https://doi.org/10.1038/s41579-020-00507-2>.
102. Shapiro MR, Fritz CL, Tait K, Paddock CD, Nicholson WL, Abramowicz KF, Karpathy SE, Dasch GA, Sumner JW, Adem PV, Scott JJ, Padgett KA, Zaki SR, Eremeeva ME. 2010. *Rickettsia* 364D: a newly recognized cause of eschar-associated illness in California. *Clin Infect Dis* 50:541–548. <https://doi.org/10.1086/649926>.
103. Denison AM, Amin BD, Nicholson WL, Paddock CD. 2014. Detection of *Rickettsia rickettsii*, *Rickettsia parkeri*, and *Rickettsia akari* in skin biopsy specimens using a multiplex real-time polymerase chain reaction assay. *Clin Infect Dis* 59:635–642. <https://doi.org/10.1093/cid/ciu358>.
104. Curto P, Simoes I, Riley SP, Martinez JJ. 2016. Differences in intracellular fate of two spotted fever group *Rickettsia* in macrophage-like cells. *Front Cell Infect Microbiol* 6:80. <https://doi.org/10.3389/fcimb.2016.00080>.
105. Fitzsimmons L, Clark T, Hackstadt T. 2021. Nitric oxide inhibition of *Rickettsia rickettsii*. *Infect Immun* 89:e00371–21. <https://doi.org/10.1128/IAI.00371-21>.
106. Kristof MN, Allen PE, Yutzy LD, Thibodaux B, Paddock CD, Martinez JJ. 2021. Significant growth by *Rickettsia* species within human macrophage-like cells is a phenotype correlated with the ability to cause disease in mammals. *Pathogens* 10:228. <https://doi.org/10.3390/pathogens10020228>.
107. Smalley C, Bechelli J, Rockx-Brouwer D, Saito T, Azar SR, Ismail N, Walker DH, Fang R. 2016. *Rickettsia australis* activates inflammasome in human and murine macrophages. *PLoS One* 11:e0157231. <https://doi.org/10.1371/journal.pone.0157231>.

108. Engström P, Burke TP, Mitchell G, Ingabire N, Mark KG, Golovkine G, Iavarone AT, Rape M, Cox JS, Welch MD. 2019. Evasion of autophagy mediated by *Rickettsia* surface protein OmpB is critical for virulence. *Nat Microbiol* 4:2538–2551. <https://doi.org/10.1038/s41564-019-0583-6>.
109. Pahlson C, Lu X, Ott M, Nilsson K. 2021. Characteristics of in vitro infection of human monocytes, by *Rickettsia helvetica*. *Microbes Infect* 23:104776. <https://doi.org/10.1016/j.micinf.2020.11.003>.
110. Allen PE, Noland RC, Martinez JJ. 2021. *Rickettsia conorii* survival in THP-1 macrophages involves host lipid droplet alterations and active rickettsial protein production. *Cell Microbiol* 23:e13390. <https://doi.org/10.1111/cmi.13390>.
111. Curto P, Santa C, Allen P, Manadas B, Simões I, Martinez JJ. 2019. A pathogen and a non-pathogen spotted fever group *Rickettsia* trigger differential proteome signatures in macrophages. *Front Cell Infect Microbiol* 9:43. <https://doi.org/10.3389/fcimb.2019.00043>.
112. Engstrom P, Burke TP, Tran CJ, Iavarone AT, Welch MD. 2021. Lysine methylation shields an intracellular pathogen from ubiquitylation and autophagy. *Sci Adv* 7:eabg2517. <https://doi.org/10.1126/sciadv.abg2517>.
113. Burke TP, Engström P, Chavez RA, Fonbuena JA, Vance RE, Welch MD. 2020. Inflammasome-mediated antagonism of type I interferon enhances *Rickettsia* pathogenesis. *Nat Microbiol* 5:688–696. <https://doi.org/10.1038/s41564-020-0673-5>.
114. Rumfield C, Hyseni I, McBride JW, Walker DH, Fang R. 2020. Activation of ASC inflammasome driven by Toll-like receptor 4 contributes to host immunity against rickettsial infection. *Infect Immun* 88:e00886-19. <https://doi.org/10.1128/IAI.00886-19>.
115. Tedesco S, De Majo F, Kim J, Trenti A, Trevisi L, Fadini GP, Bolego C, Zandstra PW, Cignarella A, Vitiello L. 2018. Convenience versus biological significance: are PMA-differentiated THP-1 cells a reliable substitute for blood-derived macrophages when studying in vitro polarization? *Front Pharmacol* 9:71. <https://doi.org/10.3389/fphar.2018.00071>.
116. Mestas J, Hughes CC. 2004. Of mice and not men: differences between mouse and human immunology. *J Immunol* 172:2731–2738. <https://doi.org/10.4049/jimmunol.172.5.2731>.
117. Parola P, Paddock CD, Raoult D. 2005. Tick-borne rickettsioses around the world: emerging diseases challenging old concepts. *Clin Microbiol Rev* 18:719–756. <https://doi.org/10.1128/CMR.18.4.719-756.2005>.
118. Parola P, Paddock CD, Socolovschi C, Labruna MB, Mediannikov O, Kernif T, Abdad MY, Stenos J, Bitam I, Fournier P-E, Raoult D. 2013. Update on tick-borne rickettsioses around the world: a geographic approach. *Clin Microbiol Rev* 26:657–702. <https://doi.org/10.1128/CMR.00032-13>.
119. Piotrowski M, Rymaszewska A. 2020. Expansion of tick-borne rickettsioses in the world. *Microorganisms* 8:1906. <https://doi.org/10.3390/microorganisms8121906>.
120. Parker RR, Kohls GM, Cox GW, Davis GE. 1939. Observations on an infectious agent from *Amblyomma maculatum*. *Public Health Rep* 54:1482–1484. <https://doi.org/10.2307/4582985>.
121. Paddock CD, Sumner JW, Comer JA, Zaki SR, Goldsmith CS, Goddard J, McLellan SLF, Tamminga CL, Ohl CA. 2004. *Rickettsia parkeri*: a newly recognized cause of spotted fever rickettsiosis in the United States. *Clin Infect Dis* 38:805–811. <https://doi.org/10.1086/381894>.
122. Paddock CD, Finley RW, Wright CS, Robinson HN, Schrodt BJ, Lane CC, Ekenna O, Blass MA, Tamminga CL, Ohl CA, McLellan SLF, Goddard J, Holman RC, Openshaw JJ, Sumner JW, Zaki SR, Eremeeva ME. 2008. *Rickettsia parkeri* rickettsiosis and its clinical distinction from Rocky Mountain spotted fever. *Clin Infect Dis* 47:1188–1196. <https://doi.org/10.1086/592254>.
123. Straily A, Feldpausch A, Ulbrich C, Schell K, Casillas S, Zaki SR, Denison AM, Condit M, Gabel J, Paddock CD. 2016. Notes from the field: *Rickettsia parkeri* rickettsiosis—Georgia, 2012–2014. *MMWR Morb Mortal Wkly Rep* 65:718–719. <https://doi.org/10.15585/mmwr.mm6528a3>.
124. Yaglom HD, Casal M, Carson S, O'Grady CL, Dominguez V, Singleton J, Chung I, Lodge H, Paddock CD. 2020. Expanding recognition of *Rickettsia parkeri* rickettsiosis in southern Arizona, 2016–2017. *Vector Borne Zoonotic Dis* 20:82–87. <https://doi.org/10.1089/vbz.2019.2491>.
125. Silva-Ramos CR, Hidalgo M, Faccini-Martinez AA. 2021. Clinical, epidemiological, and laboratory features of *Rickettsia parkeri* rickettsiosis: a systematic review. *Ticks Tick Borne Dis* 12:101734. <https://doi.org/10.1016/j.ttbdis.2021.101734>.
126. Karpathy SE, Paddock CD, Grizzard SL, Batra D, Rowe LA, Gauthier DT. 2021. Complete genome sequence of *Rickettsia parkeri* strain Black Gap. *Microbiol Resour Annot* 10:e00623-21. <https://doi.org/10.1128/MRA.00623-21>.
127. Lado P, Castro O, Labruna MB, Venzal JM. 2014. First molecular detection of *Rickettsia parkeri* in *Amblyomma tigrinum* and *Amblyomma dubitatum* ticks from Uruguay. *Ticks Tick Borne Dis* 5:660–662. <https://doi.org/10.1016/j.ttbdis.2014.04.021>.
128. Cohen SB, Yabsley MJ, Garrison LE, Freye JD, Dunlap BG, Dunn JR, Mead DG, Jones TF, Moncayo AC. 2009. *Rickettsia parkeri* in *Amblyomma americanum* ticks, Tennessee and Georgia, USA. *Emerg Infect Dis* 15:1471–1473. <https://doi.org/10.3201/eid1509.090330>.
129. Paddock CD, Fournier P-E, Sumner JW, Goddard J, Elshenawy Y, Metcalfe MG, Loftis AD, Varela-Stokes A. 2010. Isolation of *Rickettsia parkeri* and identification of a novel spotted fever group *Rickettsia* sp. from Gulf Coast ticks (*Amblyomma maculatum*) in the United States. *Appl Environ Microbiol* 76:2689–2696. <https://doi.org/10.1128/AEM.02737-09>.
130. Phillips VC, Ziemann EA, Kim C-H, Stone CM, Tuten HC, Jiménez FA. 2020. Documentation of the expansion of the Gulf Coast tick (*Amblyomma maculatum*) and *Rickettsia parkeri*: first report in Illinois. *J Parasitol* 106:9–13. <https://doi.org/10.1645/19-118>.
131. Maestas LP, Reeser SR, McGay PJ, Buoni MH. 2020. Surveillance for *Amblyomma maculatum* (Acari: Ixodidae) and *Rickettsia parkeri* (Rickettsiales: Rickettsiaceae) in the State of Delaware, and their public health implications. *J Med Entomol* 57:979–983. <https://doi.org/10.1093/jme/tjz255>.
132. Allerdice MEJ, Paddock CD, Hecht JA, Goddard J, Karpathy SE. 2021. Phylogenetic differentiation of *Rickettsia parkeri* reveals broad dispersal and distinct clustering within North American strains. *Microbiol Spectr* 9:e01417-21. <https://doi.org/10.1128/Spectrum.01417-21>.
133. Romer Y, Borrás P, Govedic F, Nava S, Carranza JI, Santini S, Armitano R, Lloveras S. 2020. Clinical and epidemiological comparison of *Rickettsia parkeri* rickettsiosis, related to *Amblyomma triste* and *Amblyomma tigrinum*, in Argentina. *Ticks Tick Borne Dis* 11:101436. <https://doi.org/10.1016/j.ttbdis.2020.101436>.
134. McGinn J, Lamason RL. 2021. The enigmatic biology of rickettsiae: recent advances, open questions and outlook. *Pathog Dis* 79:ftab019. <https://doi.org/10.1093/femspd/ftab019>.
135. Liu Z-M, Tucker AM, Driskell LO, Wood DO. 2007. Mariner-based transposon mutagenesis of *Rickettsia prowazekii*. *Appl Environ Microbiol* 73:6644–6649. <https://doi.org/10.1128/AEM.01727-07>.
136. Clark TR, Lackey AM, Kleba B, Driskell LO, Lutter El, Martens C, Wood DO, Hackstadt T. 2011. Transformation frequency of a mariner-based transposon in *Rickettsia rickettsii*. *J Bacteriol* 193:4993–4995. <https://doi.org/10.1128/JB.05279-11>.
137. Lamason RL, Kafai NM, Welch MD. 2018. A streamlined method for transposon mutagenesis of *Rickettsia parkeri* yields numerous mutations that impact infection. *PLoS One* 13:e0197012. <https://doi.org/10.1371/journal.pone.0197012>.
138. Reed SCO, Lamason RL, Risca VI, Abernathy E, Welch MD. 2014. *Rickettsia* actin-based motility occurs in distinct phases mediated by different actin nucleators. *Curr Biol* 24:98–103. <https://doi.org/10.1016/j.cub.2013.11.025>.
139. Lamason RL, Bastounis E, Kafai NM, Serrano R, Del Álamo JC, Theriot JA, Welch MD. 2016. *Rickettsia* Sca4 reduces vinculin-mediated intercellular tension to promote spread. *Cell* 167:670–683.e10. <https://doi.org/10.1016/j.cell.2016.09.023>.
140. Harris EK, Jirakanwisal K, Verhoeve VI, Fongsaran C, Suwanbongkot C, Welch MD, Macaluso KR. 2018. Role of Sca2 and RickA in the dissemination of *Rickettsia parkeri* in *Amblyomma maculatum*. *Infect Immun* 86:e00123-18. <https://doi.org/10.1128/IAI.00123-18>.
141. Iveriebor BC, Nqoro A, Obi CL. 2020. *Rickettsia africae* an agent of African tick bite fever in ticks collected from domestic animals in Eastern Cape, South Africa. *Pathogens* 9:631. <https://doi.org/10.3390/pathogens9080631>.
142. Jongejan F, Berger L, Busser S, Deetman I, Jochems M, Leenders T, de Sitter B, van der Steen F, Wentzel J, Stoltz H. 2020. *Amblyomma hebraeum* is the predominant tick species on goats in the Mnisi Community Area of Mpumalanga Province South Africa and is co-infected with *Ehrlichia ruminantium* and *Rickettsia africae*. *Parasit Vectors* 13:172. <https://doi.org/10.1186/s13071-020-04059-5>.
143. Magaia V, Taviani E, Cangi N, Neves L. 2020. Molecular detection of *Rickettsia africae* in *Amblyomma* ticks collected in cattle from southern and central Mozambique. *J Infect Dev Ctries* 14:614–622. <https://doi.org/10.3855/jidc.11625>.
144. Pillay AD, Mukaratirwa S. 2020. Genetic diversity of *Rickettsia africae* isolates from *Amblyomma hebraeum* and blood from cattle in the Eastern Cape province of South Africa. *Exp Appl Acarol* 82:529–541. <https://doi.org/10.1007/s10493-020-00555-6>.
145. Kelly PJ, Mason PR. 1991. Transmission of a spotted fever group rickettsia by *Amblyomma hebraeum* (Acari: Ixodidae). *J Med Entomol* 28:598–600. <https://doi.org/10.1093/jmedent/28.5.598>.
146. Mazhetese E, Lukanji Z, Byaruhanga C, Neves L, Morar-Leather D. 2022. *Rickettsia africae* infection rates and transovarial transmission in *Amblyomma hebraeum* ticks in Mnisi, Bushbuckridge, South Africa. *Exp Appl Acarol* 86:407–418. <https://doi.org/10.1007/s10493-022-00696-w>.

147. Keller C, Krüger A, Schwarz NG, Rakotozandrindrainy R, Rakotondrainiarivelo JP, Razafindrabe T, Derschum H, Silaghi C, Pothmann D, Veit A, Hogan B, May J, Girmann M, Krammer S, Fleischer B, Poppert S. 2016. High detection rate of *Rickettsia africae* in *Amblyomma variegatum* but low prevalence of anti-rickettsial antibodies in healthy pregnant women in Madagascar. *Ticks Tick Borne Dis* 7:60–65. <https://doi.org/10.1016/j.ttbdis.2015.08.005>.
148. Kelly PJ, Mason PR, Manning T, Slater S. 1991. Role of cattle in the epidemiology of tick-bite fever in Zimbabwe. *J Clin Microbiol* 29:256–259. <https://doi.org/10.1128/jcm.29.2.256-259.1991>.
149. Barradas PF, Mesquita JR, Ferreira P, Gärtner F, Carvalho M, Inácio E, Chivinda E, Katimba A, Amorim I. 2021. Molecular identification and characterization of *Rickettsia* spp. and other tick-borne pathogens in cattle and their ticks from Huambo, Angola. *Ticks Tick Borne Dis* 12:101583. <https://doi.org/10.1016/j.ttbdis.2020.101583>.
150. Maina AN, Jiang J, Omulo SA, Cutler SJ, Ade F, Ogola E, Feikin DR, Njenga MK, Cleaveland S, Mpoke S, Ng'ang'a Z, Breiman RF, Knobel DL, Richards AL. 2014. High prevalence of *Rickettsia africae* variants in *Amblyomma variegatum* ticks from domestic mammals in rural western Kenya: implications for human health. *Vector Borne Zoonotic Dis* 14:693–702. <https://doi.org/10.1089/vbz.2014.1578>.
151. Jensenius M, Fournier P-E, Vene S, Hoel T, Hasle G, Henriksen AZ, Hellum KB, Raoult D, Myrvang B, Norwegian African Tick Bite Fever Study Group. 2003. African tick bite fever in travelers to rural sub-Equatorial Africa. *Clin Infect Dis* 36:1411–1417. <https://doi.org/10.1086/375083>.
152. Cherry CC, Denison AM, Kato CY, Thornton K, Paddock CD. 2018. Diagnosis of spotted fever group rickettsioses in U.S. travelers returning from Africa, 2007–2016. *Am J Trop Med Hyg* 99:136–142. <https://doi.org/10.4269/ajtmh.17-0882>.
153. Dupont HT, Brouqui P, Faugere B, Raoult D. 1995. Prevalence of antibodies to *Coxiella burnetii*, *Rickettsia conorii*, and *Rickettsia typhi* in seven African countries. *Clin Infect Dis* 21:1126–1133. <https://doi.org/10.1093/clinids/21.5.1126>.
154. Heinrich N, Dill T, Dobler G, Clowes P, Kroidl I, Starke M, Ntinginya NE, Maboko L, Löscher T, Hoelscher M, Saathoff E. 2015. High seroprevalence for spotted fever group rickettsiae, is associated with higher temperatures and rural environment in Mbeya region, southwestern Tanzania. *PLoS Negl Trop Dis* 9:e0003626. <https://doi.org/10.1371/journal.pntd.0003626>.
155. Thiga JW, Mutai BK, Eyako WK, Ng'ang'a Z, Jiang J, Richards AL, Waitumbi JN. 2015. High seroprevalence of antibodies against spotted fever and scrub typhus bacteria in patients with febrile illness, Kenya. *Emerg Infect Dis* 21:688–691. <https://doi.org/10.3201/eid2104.141387>.
156. Burke DS, Mpoudi-Ngole E, Ndip LM, Bissong MA, LeBreton M, Djoko C, Biswas HH, Wolfe ND, Ndip RN, Prosser AT, Nfonsam LE, Tamoufe U. 2011. Risk factors for African tick-bite fever in rural central Africa. *Am J Trop Med Hyg* 84:608–613. <https://doi.org/10.4269/ajtmh.2011.10-0191>.
157. Ndip LM, Bouyer DH, Travassos Da Rosa APA, Titanji VPK, Tesh RB, Walker DH. 2004. Acute spotted fever rickettsiosis among febrile patients, Cameroon. *Emerg Infect Dis* 10:432–437. <https://doi.org/10.3201/eid1003.020713>.
158. Cicculi V, de Lamballerie X, Charrel R, Falchi A. 2019. First molecular detection of *Rickettsia africae* in a tropical bont tick, *Amblyomma variegatum*, collected in Corsica, France. *Exp Appl Acarol* 77:207–214. <https://doi.org/10.1007/s10493-018-00336-2>.
159. Pintore E, Olivieri E, Floriano AM, Sasseria D, Sanna N, Garippa G. 2021. First detection of *Amblyomma variegatum* and molecular finding of *Rickettsia africae* in Sardinia, Italy. *Ticks Tick Borne Dis* 12:101561. <https://doi.org/10.1016/j.ttbdis.2020.101561>.
160. Jensenius M, Fournier PE, Raoult D. 2004. Tick-borne rickettsioses in international travellers. *Int J Infect Dis* 8:139–146. <https://doi.org/10.1016/j.ijid.2003.06.004>.
161. Duval R, Merrill PT. 2016. Spotted fever group *Rickettsia* retinitis in a traveler to Africa. *Retin Cases Brief Rep* 10:89–92. <https://doi.org/10.1097/ICB.0000000000000168>.
162. Nilsson K, Wallmenius K, Rundlof-Nygren P, Stromdahl S, Pahlson C. 2017. African tick bite fever in returning Swedish travellers. Report of two cases and aspects of diagnostics. *Infect Ecol Epidemiol* 7:1343081. <https://doi.org/10.1080/2008686.2017.1343081>.
163. Roch N, Epaulard O, Pelloux I, Pavese P, Brion J-P, Raoult D, Maurin M. 2008. African tick bite fever in elderly patients: 8 cases in French tourists returning from South Africa. *Clin Infect Dis* 47:e28–e35. <https://doi.org/10.1086/589868>.
164. Zhang JZ, Fan MY, Wu YM, Fournier PE, Roux V, Raoult D. 2000. Genetic classification of “*Rickettsia heilongjiangii*” and “*Rickettsia hulini*,” two Chinese spotted fever group rickettsiae. *J Clin Microbiol* 38:3498–3501. <https://doi.org/10.1128/JCM.38.9.3498-3501.2000>.
165. Duan C, Tong Y, Huang Y, Wang X, Xiong X, Wen B. 2011. Complete genome sequence of *Rickettsia heilongjiangensis*, an emerging tick-transmitted human pathogen. *J Bacteriol* 193:5564–5565. <https://doi.org/10.1128/JB.05852-11>.
166. Mediannikov OY, Sidelnikov Y, Ivanov L, Mokretsova E, Fournier P-E, Tarasevich I, Raoult D. 2004. Acute tick-borne rickettsiosis caused by *Rickettsia heilongjiangensis* in Russian Far East. *Emerg Infect Dis* 10:810–817. <https://doi.org/10.3201/eid1005.030437>.
167. Mediannikov O, Makarova V, Tarasevich I, Sidelnikov Y, Raoult D. 2009. Isolation of *Rickettsia heilongjiangensis* strains from humans and ticks and its multispacer typing. *Clin Microbiol Infect* 15(Suppl 2):288–289. <https://doi.org/10.1111/j.1469-0691.2008.02239.x>.
168. Wang Q, Pan Y-S, Jiang B-G, Ye R-Z, Chang Q-C, Shao H-Z, Cui X-M, Xu D-L, Li L-F, Wei W, Xia L-Y, Li J, Zhao L, Guo W-B, Zhou Y-H, Jiang J-F, Jia N, Cao W-C. 2021. Prevalence of multiple tick-borne pathogens in various tick vectors in northeastern China. *Vector Borne Zoonotic Dis* 21:162–171. <https://doi.org/10.1089/vbz.2020.2712>.
169. Igolkina Y, Rar V, Vysochina N, Ivanov L, Tikunov A, Pukhovskaya N, Epikhina T, Golovljova I, Tikunova N. 2018. Genetic variability of *Rickettsia* spp. in Dermacentor and Haemaphysalis ticks from the Russian Far East. *Ticks Tick Borne Dis* 9:1594–1603. <https://doi.org/10.1016/j.ttbdis.2018.07.015>.
170. Jiang J, An H, Lee JS, O'Guinn ML, Kim H-C, Chong S-T, Zhang Y, Song D, Burrus RG, Bao Y, Klein TA, Richards AL. 2018. Molecular characterization of *Haemaphysalis longicornis*-borne rickettsiae, Republic of Korea and China. *Ticks Tick Borne Dis* 9:1606–1613. <https://doi.org/10.1016/j.ttbdis.2018.07.013>.
171. Duan C, Meng Y, Wang X, Xiong X, Wen B. 2011. Exploratory study on pathogenesis of Far-Eastern spotted fever. *Am J Trop Med Hyg* 85:504–509. <https://doi.org/10.4269/ajtmh.2011.10-0660>.
172. Qi Y, Xiong X, Duan C, Jiao J, Gong W, Wen B. 2013. Recombinant protein YbgF induces protective immunity against *Rickettsia heilongjiangensis* infection in C3H/HeN mice. *Vaccine* 31:5643–5650. <https://doi.org/10.1016/j.vaccine.2013.09.064>.
173. Meng Y, Xiong X, Qi Y, Duan C, Gong W, Jiao J, Wen B. 2015. Protective immunity against *Rickettsia heilongjiangensis* in a C3H/HeN mouse model mediated by outer membrane protein B-pulsed dendritic cells. *Sci China Life Sci* 58:287–296. <https://doi.org/10.1007/s11427-014-4720-4>.
174. Yang X, Jiao J, Han G, Gong W, Wang X, Xiong X, Wen B. 2016. Enhanced expression of T-cell immunoglobulin and mucin domain protein 3 in endothelial cells facilitates intracellular killing of *Rickettsia heilongjiangensis*. *J Infect Dis* 213:71–79. <https://doi.org/10.1093/infdis/jiv463>.
175. Kollars TM, Jr, Tippayachai B, Bodhidatta D. 2001. Short report: Thai tick typhus, *Rickettsia honei*, and a unique rickettsia detected in *Ixodes granulatus* (Ixodidae: Acari) from Thailand. *Am J Trop Med Hyg* 65:535–537. <https://doi.org/10.4269/ajtmh.2001.65.535>.
176. Jiang J, Sangkasuwan V, Lerdthusnee K, Sukwit S, Chuenchitra T, Rozmajzl PJ, Eamsila C, Jones JW, Richards AL. 2005. Human infection with *Rickettsia honei*, Thailand. *Emerg Infect Dis* 11:1473–1475. <https://doi.org/10.3201/eid1109.050011>.
177. Stenos J, Roux V, Walker D, Raoult D. 1998. *Rickettsia honei* sp. nov., the aetiological agent of Flinders Island spotted fever in Australia. *Int J Syst Bacteriol* 48(Part 4):1399–1404. <https://doi.org/10.1099/00207713-48-4-1399>.
178. Whitworth T, Popov V, Han V, Bouyer D, Stenos J, Graves S, Ndip L, Walker D. 2003. Ultrastructural and genetic evidence of a reptilian tick, *Aponomma hydrosauri*, as a host of *Rickettsia honei* in Australia: possible transovarial transmission. *Ann N Y Acad Sci* 990:67–74. <https://doi.org/10.1111/j.1749-6632.2003.tb07339.x>.
179. Xin D, El Karkouri K, Robert C, Raoult D, Fournier P-E. 2012. Genomic comparison of *Rickettsia honei* strain RBT and other *Rickettsia* species. *J Bacteriol* 194:4145. <https://doi.org/10.1128/JB.00802-12>.
180. Whiley H, Custance G, Graves S, Stenos J, Taylor M, Ross K, Gardner M. 2016. *Rickettsia* detected in the reptile tick *Bothriocroton hydrosauri* from the lizard *Tiliqua rugosa* in South Australia. *Pathogens* 5:41. <https://doi.org/10.3390/pathogens5020041>.
181. Taggart PL, Traub R, Fui S, Weinstein P. 2018. Attempt to uncover reservoirs of human spotted fever rickettsiosis on the Fleurieu Peninsula, South Australia. *J Vector Borne Dis* 55:239–241. <https://doi.org/10.4103/0972-9062.249483>.
182. Unsworth NB, Stenos J, Graves SR, Faa AG, Cox GE, Dyer JR, Boutlis CS, Lane AM, Shaw MD, Robson J, Nissen MD. 2007. Flinders Island spotted fever rickettsioses caused by “*marmionii*” strain of *Rickettsia honei*, eastern Australia. *Emerg Infect Dis* 13:566–573. <https://doi.org/10.3201/eid1304.060087>.
183. Unsworth N, Graves S, Nguyen C, Kemp G, Graham J, Stenos J. 2008. Markers of exposure to spotted fever rickettsiae in patients with chronic illness, including fatigue, in two Australian populations. *QJM* 101:269–274. <https://doi.org/10.1093/qjmed/hcm149>.

184. Graham RMA, Donohue S, McMahon J, Jennison AV. 2017. Detection of spotted fever group Rickettsia DNA by deep sequencing. *Emerg Infect Dis* 23:1911–1913. <https://doi.org/10.3201/eid2311.170474>.
185. Murphy H, Renvoise A, Pandey P, Parola P, Raoult D. 2011. Rickettsia honei infection in human, Nepal, 2009. *Emerg Infect Dis* 17:1865–1867. <https://doi.org/10.3201/eid1710.101943>.
186. Denison AM, Leitgeb B, Obadiah JM, Schwindt A, Ladd-Wilson SG, Paddock CD, Matkovic E. 2021. Rickettsia honei infection in a traveler returning from India. *Open Forum Infect Dis* 8:ofaa636. <https://doi.org/10.1093/ofid/ofaa636>.
187. Robertson RG, Wisseman CL, Jr. 1973. Tick-borne rickettsiae of the spotted fever group in West Pakistan. II. Serological classification of isolates from West Pakistan and Thailand: evidence for two new species. *Am J Epidemiol* 97:55–64. <https://doi.org/10.1093/oxfordjournals.aje.a121485>.
188. Dahlgren FS, Paddock CD, Springer YP, Eisen RJ, Behravesh CB. 2016. Expanding range of Amblyomma americanum and simultaneous changes in the epidemiology of spotted fever group rickettsiosis in the United States. *Am J Trop Med Hyg* 94:35–42. <https://doi.org/10.4269/ajtmh.15-0580>.
189. Wojan C, Thrasher T, Lacey E, Clay K. 2022. Distribution, dynamics, and diversity of questing ticks in the lower Midwest. *J Med Entomol* 59: 273–282. <https://doi.org/10.1093/jme/tjab155>.
190. Rosenberg R, Lindsey NP, Fischer M, Gregory CJ, Hinckley AF, Mead PS, Paz-Bailey G, Waterman SH, Drexler NA, Kersh GJ, Hooks H, Partridge SK, Visser SN, Beard CB, Petersen LR. 2018. Vital signs: trends in reported vectorborne disease cases—United States and Territories, 2004–2016. *MMWR Morb Mortal Wkly Rep* 67:496–501. <https://doi.org/10.15585/mmwr.mm6717e1>.
191. Sanchez-Vicente S, Tagliafierro T, Coleman JL, Benach JL, Tokarz R. 2019. Polymicrobial nature of tick-borne diseases. *mBio* 10:e02055-19. <https://doi.org/10.1128/mBio.02055-19>.
192. Costa FB, da Costa AP, Moraes-Filho J, Martins TF, Soares HS, Ramirez DG, Dias RA, Labruna MB. 2017. Rickettsia amblyommatis infecting ticks and exposure of domestic dogs to Rickettsia spp. in an Amazon-Cerrado transition region of northeastern Brazil. *PLoS One* 12:e0179163. <https://doi.org/10.1371/journal.pone.0179163>.
193. Lopes MG, Krawczak FDS, de Lima JTR, Fournier GFDSR, Acosta IDCL, Ramirez DG, Marcili A, Labruna MB, Gennari SM. 2019. Occurrence of Ehrlichia canis and Hepatozoon canis and probable exposure to Rickettsia amblyommatis in dogs and cats in Natal, RN. *Rev Bras Parasitol Vet* 28: 151–156. <https://doi.org/10.1590/S1984-296120180065>.
194. Childs JE, Paddock CD. 2003. The ascendancy of Amblyomma americanum as a vector of pathogens affecting humans in the United States. *Annu Rev Entomol* 48:307–337. <https://doi.org/10.1146/annurev.ento.48.091801.112728>.
195. Araujo RN, Franco PF, Rodrigues H, Santos LCB, McKay CS, Sanhueza CA, Brito CRN, Azevedo MA, Venuto AP, Cowan PJ, Almeida IC, Finn MG, Marques AF. 2016. Amblyomma sculptum tick saliva: alpha-Gal identification, antibody response and possible association with red meat allergy in Brazil. *Int J Parasitol* 46:213–220. <https://doi.org/10.1016/j.ijpara.2015.12.005>.
196. Hashizume H, Fujiyama T, Umayahara T, Kageyama R, Walls AF, Satoh T. 2018. Repeated Amblyomma testudinarium tick bites are associated with increased galactose-alpha-1,3-galactose carbohydrate IgE antibody levels: a retrospective cohort study in a single institution. *J Am Acad Dermatol* 78:1135–1141.e3. <https://doi.org/10.1016/j.jaad.2017.12.028>.
197. Mitchell CL, Lin F-C, Vaughn M, Apperson CS, Meshnick SR, Commins SP. 2020. Association between Lone Star tick bites and increased alpha-gal sensitization: evidence from a prospective cohort of outdoor workers. *Parasit Vectors* 13:470. <https://doi.org/10.1186/s13071-020-04343-4>.
198. Billeter SA, Blanton HL, Little SE, Levy MG, Breitschwerdt EB. 2007. Detection of Rickettsia amblyommii in association with a tick bite rash. *Vector Borne Zoonotic Dis* 7:607–610. <https://doi.org/10.1089/vbz.2007.0121>.
199. Apperson CS, Engber B, Nicholson WL, Mead DG, Engel J, Yabsley MJ, Dail K, Johnson J, Watson DW. 2008. Tick-borne diseases in North Carolina: is ‘Rickettsia amblyommii’ a possible cause of rickettsiosis reported as Rocky Mountain spotted fever? *Vector Borne Zoonotic Dis* 8:597–606. <https://doi.org/10.1089/vbz.2007.0271>.
200. Delisle J, Mendell NL, Stull-Lane A, Bloch KC, Bouyer DH, Moncayo AC. 2016. Human infections by multiple spotted fever group rickettsiae in Tennessee. *Am J Trop Med Hyg* 94:1212–1217. <https://doi.org/10.4269/ajtmh.15-0372>.
201. Vaughn MF, Delisle J, Johnson J, Daves G, Williams C, Reber J, Mendell NL, Bouyer DH, Nicholson WL, Moncayo AC, Meshnick SR. 2014. Seroepidemiologic study of human infections with spotted fever group rickettsiae in North Carolina. *J Clin Microbiol* 52:3960–3966. <https://doi.org/10.1128/JCM.01733-14>.
202. Blanton LS, Mendell NL, Walker DH, Bouyer DH. 2014. ‘Rickettsia amblyommii’ induces cross protection against lethal Rocky Mountain spotted fever in a guinea pig model. *Vector Borne Zoonotic Dis* 14:557–562. <https://doi.org/10.1089/vbz.2014.1575>.
203. Rivas JJ, Moreira-Soto A, Alvarado G, Taylor L, Calderón-Arguedas O, Hun L, Corrales-Aguilar E, Morales JA, Troyo A. 2015. Pathogenic potential of a Costa Rican strain of ‘Candidatus Rickettsia amblyommii’ in guinea pigs (Cavia porcellus) and protective immunity against Rickettsia rickettsii. *Ticks Tick Borne Dis* 6:805–811. <https://doi.org/10.1016/j.ttbdis.2015.07.008>.
204. Snellgrove AN, Krapianaya I, Scott P, Levin ML. 2021. Assessment of the pathogenicity of Rickettsia amblyommatis, Rickettsia bellii, and Rickettsia montanensis in a guinea pig model. *Vector Borne Zoonotic Dis* 21: 232–241. <https://doi.org/10.1089/vbz.2020.2695>.

Hwan Keun Kim, Ph.D., is an Assistant Professor in the Department of Microbiology and Immunology at Stony Brook University, located in Long Island, NY. He received his Ph.D. in microbiology under the mentorship of Dr. Schneewind and Dr. Missiakas at the University of Chicago. His Ph.D. research focused on understanding *S. aureus* immune evasion mechanisms and developing vaccine antigens for *S. aureus* recurrent infections. During his postdoctoral research at the Howard T. Ricketts Laboratory, he transitioned to the study of rickettsial pathogenesis and developed a novel transposon mutagenesis system for *Rickettsia*. At Stony Brook University, his laboratory studies tick-borne pathogens that brought pestilential mortality and morbidity throughout human history and continue to pose a significant threat to public health. In particular, his research focuses on identifying microbial genes important for the pathogenic life cycle in mammalian hosts and arthropod vectors and identifying the underlying molecular mechanisms associated with pathogenesis, transmission, and immune evasion.

